LEGISLATURE OF NEBRASKA ONE HUNDRED EIGHTH LEGISLATURE FIRST SESSION

LEGISLATIVE BILL 22

Introduced by Wayne, 13.

Read first time January 05, 2023

Committee: Judiciary

| 1 | A BILL FOR AN ACT relating to marijuana; to amend sections 2-505, 2-506, |
|----|--|
| 2 | 2-509, 28-417, 28-419, 28-439, 77-4301, 77-4302, 77-4303, 77-4304, |
| 3 | 77-4305, 77-4306, 77-4309, 77-4310.01, and 77-4310.03, Reissue |
| 4 | Revised Statutes of Nebraska, and sections 28-401, 28-405, 28-416, |
| 5 | 28-1354, and 28-1701, Revised Statutes Cumulative Supplement, 2022; |
| 6 | to decriminalize use and possession of marijuana; to remove |
| 7 | marijuana from the marijuana and controlled substances tax; to |
| 8 | rename a fund; to eliminate obsolete provisions; to harmonize |
| 9 | provisions; to repeal the original sections; and to outright repeal |
| 10 | sections 2-5701, 28-463, 28-464, 28-465, 28-466, 28-467, 28-468, and |
| 11 | 28-469, Reissue Revised Statutes of Nebraska. |
| | |

12 Be it enacted by the people of the State of Nebraska,

-1-

Section 1. Section 2-505, Reissue Revised Statutes of Nebraska, is
 amended to read:

2-505 (1) Hemp may only be cultivated by a USDA-licensed hemp
producer or a person meeting the requirements of section 2-5701 or in
compliance with this section.

6 (2) Before a person may be licensed to cultivate hemp under the 7 Nebraska Hemp Farming Act, such person shall submit an application on a 8 form prescribed by the department that includes, but is not limited to, 9 the following:

10 (a) If the applicant is an individual, the applicant's full name,
11 birthdate, mailing address, telephone number, and valid email address;

(b) If the applicant is an entity and not an individual, (i) the name of the applicant, mailing address, telephone number, and valid email address, (ii) the full name of each officer, director, partner, member, or owner owning in excess of ten percent of equity or stock in such entity, (iii) the full name of each key participant as defined in 7 C.F.R. 990.1, and (iv) the birthdate, title, mailing address, telephone number, and valid email address of each such person or key participant;

(c) The proposed acreage to be cultivated or the square footage of agreenhouse or other indoor space to be cultivated;

(d) The street address, legal description, location ID, and GPS coordinates for each field, greenhouse, building, or other site where hemp will be cultivated. The site information may be verified by the department; and

(e) Maps depicting each site where hemp will be cultivated, with
appropriate indications for entrances, field boundaries, and specific
locations corresponding to the GPS coordinates provided under subdivision
(d) of this subsection.

(3) Before a person may be licensed to cultivate hemp under the
Nebraska Hemp Farming Act, such person shall submit with the application
a nonrefundable application fee as set by the department pursuant to

-2-

1 section 2-508.

(4) Before a person may be licensed to cultivate hemp under the 2 3 Nebraska Hemp Farming Act, such person shall submit a site registration 4 fee as set by the department pursuant to section 2-508. The site registration fee shall be paid for each separate site where the applicant 5 will cultivate hemp. Subsequent modifications to the sites listed in the 6 application shall be submitted on forms prescribed by the department 7 along with a site modification fee and shall only take effect upon 8 9 written approval of the department. The applicant must certify that all sites where hemp is to be cultivated are under the control of the 10 applicant and that the department shall have unlimited access to all such 11 sites. 12

LB22

2023

(5) After the department receives approval by the United States Secretary of Agriculture for the state plan described in section 2-516, an initial cultivator license application may be submitted at any time, except that the department may set a cutoff date for applications ahead of the growing season. An initial cultivator license issued by the department expires on December 31 in the calendar year for which it was issued.

(6) A renewal application for a license to cultivate hemp shall be submitted on forms prescribed by the department. A renewal application is due by December 31 and shall be accompanied by the cultivator license fee and the site registration fee for all sites listed in the renewal application. The renewal cultivator license is valid from January 1 or when the license is granted, whichever is later, through December 31 next following.

(7) A cultivator license shall lapse automatically upon a change of
ownership or location, and a new license must be obtained. The licensee
shall promptly provide notice of change in ownership or location to the
department.

31 (8) An application and supporting documents submitted to the

-3-

department under this section are not public records subject to disclosure pursuant to sections 84-712 to 84-712.09. Such information may be submitted to the United States Department of Agriculture pursuant to the requirements of the federal Agriculture Improvement Act of 2018 or any other federal statute, rule, or regulation, and may be submitted to law enforcement.

Sec. 2. Section 2-506, Reissue Revised Statutes of Nebraska, isamended to read:

9 2-506 (1) Except for handling by an approved testing facility, a 10 USDA-licensed hemp producer, or a cultivator licensed under section 11 2-505, a person shall not process, handle, or broker hemp plants or plant 12 parts in this state unless the person meets the requirements of section 13 2-5701 or is in compliance with this section and licensed as a processor-14 handler or broker under the Nebraska Hemp Farming Act.

15 (2) Before a person may be licensed to process, handle, or broker 16 hemp in this state, such person shall submit an application on a form 17 prescribed by the department that includes, but is not limited to, the 18 following:

(a) If the applicant is an individual, the applicant's full name,
birthdate, mailing address, telephone number, and valid email address;

(b) If the applicant is an entity and not an individual, the name of the applicant, mailing address, telephone number, and valid email address, the full name of each officer and director, partner, member, or owner owning in excess of ten percent of equity or stock in such entity, and the birthdate, title, mailing address, telephone number, and valid email address of each such person;

(c) The street address, legal description, location ID, and GPS
 coordinates for the site where hemp will be processed or handled, if
 applicable; and

30 (d) Maps depicting the site where hemp will be processed or handled,31 if applicable, with appropriate indications for entrances and specific

-4-

locations corresponding to the GPS coordinates provided under subdivision
 (c) of this subsection.

3 (3) Before a person may be licensed to process, handle, or broker
4 hemp, such person shall submit with the application a nonrefundable
5 application fee as set by the department pursuant to section 2-508.

(4) Before a person may be licensed to process or handle hemp, such 6 7 person shall submit a site registration fee as set by the department pursuant to section 2-508. The site registration fee shall be paid for 8 9 each separate site where hemp is processed or handled. Subsequent modifications to the sites listed in the application shall be submitted 10 on forms prescribed by the department along with the site modification 11 fee and shall only take effect upon written approval of the department. 12 The applicant must certify that all sites where hemp is to be processed 13 14 or handled are under the control of the applicant and that the department shall have unlimited access to all such sites. 15

(5) An initial processor-handler or broker license application may
be submitted at any time. An initial processor-handler or broker license
issued by the department expires on December 31 in the calendar year for
which it was issued.

(6) A renewal application for a processor-handler or broker license 20 shall be submitted on forms prescribed by the department. A renewal 21 application is due by December 31 and shall be accompanied by the 22 processor-handler or broker license fee and, if applicable, the site 23 24 registration fee for all sites listed in the renewal application. The 25 renewal processor-handler or broker license is valid from January 1 or when the license is granted, whichever is later, through December 31 next 26 following. 27

(7) A processor-handler or broker license shall lapse automatically
upon a change of ownership or location, and a new license must be
obtained. The licensee shall promptly provide notice of change in
ownership or location to the department.

-5-

(8) A processor-handler licensee who also brokers hemp shall not be required to also obtain a broker license under this section.

LB22

2023

3 (9) An application and supporting documents submitted to the 4 department under this section are not public records subject to 5 disclosure pursuant to sections 84-712 to 84-712.09. Such information may 6 be submitted to the United States Department of Agriculture pursuant to 7 the requirements of the federal Agriculture Improvement Act of 2018 or 8 any other federal statute, rule, or regulation, and may be submitted to 9 law enforcement.

Sec. 3. Section 2-509, Reissue Revised Statutes of Nebraska, is amended to read:

2-509 The Nebraska Hemp Program Fund is established. The fund shall 12 13 be administered by the department for the purpose of covering the costs of the department in administering sections 2-504 to 2-516 and 2-5701. 14 The fund may receive appropriations by the Legislature, gifts, grants, 15 16 federal funds, and any other funds both public and private. All fees 17 collected by the department under section sections 2-508 and 2-5701 shall be remitted to the State Treasurer for credit to the fund. Transfers from 18 19 the Nebraska Hemp Program Fund to the Noxious Weed Cash Fund may be made as provided in section 2-958. Transfers from the Nebraska Hemp Program 20 Fund to the Fertilizers and Soil Conditioners Administrative Fund may be 21 22 made as provided in section 81-2,162.27. Any money in the fund available for investment shall be invested by the state investment officer pursuant 23 24 to the Nebraska Capital Expansion Act and the Nebraska State Funds 25 Investment Act.

26 Sec. 4. Section 28-401, Revised Statutes Cumulative Supplement, 27 2022, is amended to read:

28 28-401 As used in the Uniform Controlled Substances Act, unless the29 context otherwise requires:

30 (1) Administer means to directly apply a controlled substance by31 injection, inhalation, ingestion, or any other means to the body of a

-6-

23

LB22 2023

2 (2) Agent means an authorized person who acts on behalf of or at the 3 direction of another person but does not include a common or contract 4 carrier, public warehouse keeper, or employee of a carrier or warehouse 5 keeper;

6 (3) Administration means the Drug Enforcement Administration of the
7 United States Department of Justice;

8 (4) Controlled substance means a drug, biological, substance, or 9 immediate precursor in Schedules I through V of section 28-405. 10 Controlled substance does not include distilled spirits, wine, malt 11 beverages, tobacco, hemp, or any nonnarcotic substance if such substance 12 may, under the Federal Food, Drug, and Cosmetic Act, 21 U.S.C. 301 et 13 seq., as such act existed on January 1, 2014, and the law of this state, 14 be lawfully sold over the counter without a prescription;

(5) Counterfeit substance means a controlled substance which, or the 15 16 container or labeling of which, without authorization, bears the 17 trademark, trade name, or other identifying mark, imprint, number, or device, or any likeness thereof, of a manufacturer, distributor, or 18 19 dispenser other than the person or persons who in fact manufactured, distributed, or dispensed such substance and which thereby falsely 20 purports or is represented to be the product of, or to have been 21 distributed by, such other manufacturer, distributor, or dispenser; 22

(6) Department means the Department of Health and Human Services;

(7) Division of Drug Control means the personnel of the Nebraska
State Patrol who are assigned to enforce the Uniform Controlled
Substances Act;

(8) Dispense means to deliver a controlled substance to an ultimate
user or a research subject pursuant to a medical order issued by a
practitioner authorized to prescribe, including the packaging, labeling,
or compounding necessary to prepare the controlled substance for such
delivery;

-7-

(9) Distribute means to deliver other than by administering or
 dispensing a controlled substance;

3 (10) Prescribe means to issue a medical order;

4 (11) Drug means (a) articles recognized in the official United States Pharmacopoeia, official Homeopathic Pharmacopoeia of the United 5 States, official National Formulary, or any supplement to any of them, 6 7 (b) substances intended for use in the diagnosis, cure, mitigation, treatment, or prevention of disease in human beings or animals, and (c) 8 9 substances intended for use as a component of any article specified in 10 subdivision (a) or (b) of this subdivision, but does not include devices or their components, parts, or accessories; 11

12 (12) Deliver or delivery means the actual, constructive, or
13 attempted transfer from one person to another of a controlled substance,
14 whether or not there is an agency relationship;

15

(13) Hemp has the same meaning as in section 2-503;

16 (14)(a) Marijuana means all parts of the plant of the genus 17 cannabis, whether growing or not, the seeds thereof, and every compound, 18 manufacture, salt, derivative, mixture, or preparation of such plant or 19 its seeds, including, but not limited to, tetrahydrocannabinols extracted 20 or isolated from the plant or any product or preparation containing such 21 tetrahydrocannabinols, including, but not limited to, edible products, 22 tinctures, and ointments.

(b) Marijuana does not include the mature stalks of such plant, hashish, tetrahydrocannabinols extracted or isolated from the plant, fiber produced from such stalks, oil or cake made from the seeds of such plant, any other compound, manufacture, salt, derivative, mixture, or preparation of such mature stalks, the sterilized seed of such plant which is incapable of germination, or cannabidiol contained in a drug product approved by the federal Food and Drug Administration.

30 (c) Marijuana does not include hemp or resins extracted from hemp in
 31 the possession of a person as authorized under the Nebraska Hemp Farming

-8-

1 <u>Act</u>.

2 (d) When the weight of marijuana is referred to in the Uniform 3 Controlled Substances Act, it means its weight at or about the time it is 4 seized or otherwise comes into the possession of law enforcement 5 authorities, whether cured or uncured at that time; -

6 (e) When industrial hemp as defined in section 2-5701 is in the 7 possession of a person as authorized under section 2-5701, it is not 8 considered marijuana for purposes of the Uniform Controlled Substances 9 Act;

10 (15) Manufacture means the production, preparation, propagation, conversion, or processing of a controlled substance, either directly or 11 12 indirectly, extraction from substances of natural by origin, independently by means of chemical synthesis, or by a combination of 13 14 extraction and chemical synthesis, and includes any packaging or repackaging of the substance or labeling or relabeling of its container. 15 16 Manufacture does not include the preparation or compounding of a 17 controlled substance by an individual for his or her own use, except for the preparation or compounding of components or ingredients used for or 18 19 intended to be used for the manufacture of methamphetamine, or the preparation, compounding, conversion, packaging, or labeling of a 20 controlled substance: (a) By a practitioner as an incident to his or her 21 22 prescribing, administering, or dispensing of a controlled substance in 23 the course of his or her professional practice; or (b) by a practitioner, 24 or by his or her authorized agent under his or her supervision, for the purpose of, or as an incident to, research, teaching, or chemical 25 analysis and not for sale; 26

(16) Narcotic drug means any of the following, whether produced directly or indirectly by extraction from substances of vegetable origin, independently by means of chemical synthesis, or by a combination of extraction and chemical synthesis: (a) Opium, opium poppy and poppy straw, coca leaves, and opiates; (b) a compound, manufacture, salt,

-9-

derivative, or preparation of opium, coca leaves, or opiates; or (c) a 1 2 substance and any compound, manufacture, salt, derivative, or preparation thereof which is chemically equivalent to or identical with any of the 3 4 substances referred to in subdivisions (a) and (b) of this subdivision, 5 except that the words narcotic drug as used in the Uniform Controlled Substances Act does not include decocainized coca leaves or extracts of 6 coca leaves, which extracts do not contain cocaine or ecgonine, or 7 isoquinoline alkaloids of opium; 8

9 (17) Opiate means any substance having an addiction-forming or 10 addiction-sustaining liability similar to morphine or being capable of 11 conversion into a drug having such addiction-forming or addiction-12 sustaining liability. Opiate does not include the dextrorotatory isomer 13 of 3-methoxy-n methylmorphinan and its salts. Opiate includes its racemic 14 and levorotatory forms;

(18) Opium poppy means the plant of the species Papaver somniferum
L., except the seeds thereof;

17 (19) Poppy straw means all parts, except the seeds, of the opium18 poppy after mowing;

(20) Person means any corporation, association, partnership, limited
liability company, or one or more persons;

(21) Practitioner means a physician, a physician assistant, a 21 22 dentist, a veterinarian, a pharmacist, a podiatrist, an optometrist, a certified nurse midwife, a certified registered nurse anesthetist, a 23 24 nurse practitioner, a scientific investigator, a pharmacy, a hospital, or 25 any other person licensed, registered, or otherwise permitted to distribute, dispense, prescribe, conduct research with respect to, or 26 27 administer a controlled substance in the course of practice or research 28 in this state, including an emergency medical service as defined in section 38-1207; 29

30 (22) Production includes the manufacture, planting, cultivation, or
 31 harvesting of a controlled substance;

-10-

1 (23) Immediate precursor means a substance which is the principal 2 compound commonly used or produced primarily for use and which is an 3 immediate chemical intermediary used or likely to be used in the 4 manufacture of a controlled substance, the control of which is necessary 5 to prevent, curtail, or limit such manufacture;

6

(24) State means the State of Nebraska;

7 (25) Ultimate user means a person who lawfully possesses a 8 controlled substance for his or her own use, for the use of a member of 9 his or her household, or for administration to an animal owned by him or 10 her or by a member of his or her household;

11

(26) Hospital has the same meaning as in section 71-419;

12 (27) Cooperating individual means any person, other than a 13 commissioned law enforcement officer, who acts on behalf of, at the 14 request of, or as agent for a law enforcement agency for the purpose of 15 gathering or obtaining evidence of offenses punishable under the Uniform 16 Controlled Substances Act;

17 (28)(a) Hashish or concentrated cannabis means (i) the separated 18 resin, whether crude or purified, obtained from a plant of the genus 19 cannabis or (ii) any material, preparation, mixture, compound, or other 20 substance which contains ten percent or more by weight of 21 tetrahydrocannabinols.

(b) When resins extracted from (i) industrial hemp as defined in section 2-5701 are in the possession of a person as authorized under section 2-5701 or (ii) hemp as defined in section 2-503 are in the possession of a person as authorized under the Nebraska Hemp Farming Act, they are not considered hashish or concentrated cannabis for purposes of the Uniform Controlled Substances Act.

28 (c) Hashish or concentrated cannabis does not include cannabidiol 29 contained in a drug product approved by the federal Food and Drug 30 Administration;

31 (28) (29) Exceptionally hazardous drug means (a) a narcotic drug,

-11-

1 (b) thiophene analog of phencyclidine, (c) phencyclidine, (d)
2 amobarbital, (e) secobarbital, (f) pentobarbital, (g) amphetamine, or (h)
3 methamphetamine;

(29) (30) Imitation controlled substance means a substance which is 4 not a controlled substance or controlled substance analogue but which, by 5 way of express or implied representations and consideration of other 6 7 relevant factors including those specified in section 28-445, would lead a reasonable person to believe the substance is a controlled substance or 8 9 controlled substance analogue. A placebo or registered investigational drug manufactured, distributed, possessed, or delivered in the ordinary 10 course of practice or research by a health care professional shall not be 11 deemed to be an imitation controlled substance; 12

13 (30)(a) (31)(a) Controlled substance analogue means a substance (i) the chemical structure of which is substantially similar to the chemical 14 structure of a Schedule I or Schedule II controlled substance as provided 15 in section 28-405 or (ii) which has a stimulant, depressant, analgesic, 16 17 or hallucinogenic effect on the central nervous system that is substantially similar to or greater than the stimulant, depressant, 18 analgesic, or hallucinogenic effect on the central nervous system of a 19 Schedule I or Schedule II controlled substance as provided in section 20 28-405. A controlled substance analogue shall, to the extent intended for 21 22 human consumption, be treated as a controlled substance under Schedule I 23 of section 28-405 for purposes of the Uniform Controlled Substances Act; 24 and

(b) Controlled substance analogue does not include (i) a controlled substance, (ii) any substance generally recognized as safe and effective within the meaning of the Federal Food, Drug, and Cosmetic Act, 21 U.S.C. 301 et seq., as such act existed on January 1, 2014, (iii) any substance for which there is an approved new drug application, or (iv) with respect to a particular person, any substance if an exemption is in effect for investigational use for that person, under section 505 of the Federal

-12-

Food, Drug, and Cosmetic Act, 21 U.S.C. 355, as such section existed on
 January 1, 2014, to the extent conduct with respect to such substance is
 pursuant to such exemption;

(31) (32) Anabolic steroid means any drug or hormonal substance, 4 chemically and pharmacologically related to testosterone (other than 5 estrogens, progestins, and corticosteroids), that promotes muscle growth 6 and includes any controlled substance in Schedule III(d) of section 7 28-405. Anabolic steroid does not include any anabolic steroid which is 8 9 expressly intended for administration through implants to cattle or other nonhuman species and has been approved by the Secretary of Health and 10 Human Services for such administration, but if any person prescribes, 11 dispenses, or distributes such a steroid for human use, such person shall 12 be considered to have prescribed, dispensed, or distributed an anabolic 13 steroid within the meaning of this subdivision; 14

15 (32) (33) Chart order means an order for a controlled substance 16 issued by a practitioner for a patient who is in the hospital where the 17 chart is stored or for a patient receiving detoxification treatment or 18 maintenance treatment pursuant to section 28-412. Chart order does not 19 include a prescription;

20 <u>(33)</u> (34) Medical order means a prescription, a chart order, or an 21 order for pharmaceutical care issued by a practitioner;

(34) (35) Prescription means an order for a controlled substance
 issued by a practitioner. Prescription does not include a chart order;

<u>(35)</u> (36) Registrant means any person who has a controlled
 substances registration issued by the state or the Drug Enforcement
 Administration of the United States Department of Justice;

(36) (37) Reverse distributor means a person whose primary function
 is to act as an agent for a pharmacy, wholesaler, manufacturer, or other
 entity by receiving, inventorying, and managing the disposition of
 outdated, expired, or otherwise nonsaleable controlled substances;

31 (37) (38) Signature means the name, word, or mark of a person

-13-

18

written in his or her own hand with the intent to authenticate a writing
 or other form of communication or a digital signature which complies with
 section 86-611 or an electronic signature;

4 <u>(38)</u> (39) Facsimile means a copy generated by a system that encodes 5 a document or photograph into electrical signals, transmits those signals 6 over telecommunications lines, and reconstructs the signals to create an 7 exact duplicate of the original document at the receiving end;

8 (39) (40) Electronic signature has the definition found in section
9 86-621;

<u>(40)</u> (41) Electronic transmission means transmission of information
 in electronic form. Electronic transmission includes computer-to-computer
 transmission or computer-to-facsimile transmission;

<u>(41)</u> (42) Long-term care facility means an intermediate care
 facility, an intermediate care facility for persons with developmental
 disabilities, a long-term care hospital, a mental health substance use
 treatment center, a nursing facility, or a skilled nursing facility, as
 such terms are defined in the Health Care Facility Licensure Act;

(42) (43) Compounding has the same meaning as in section 38-2811;

19 <u>(43)</u> (44) Cannabinoid receptor agonist means any chemical compound 20 or substance that, according to scientific or medical research, study, 21 testing, or analysis, demonstrates the presence of binding activity at 22 one or more of the CB1 or CB2 cell membrane receptors located within the 23 human body. Cannabinoid receptor agonist does not include cannabidiol 24 contained in a drug product approved by the federal Food and Drug 25 Administration; and

26 (44) (45) Lookalike substance means a product or substance, not 27 specifically designated as a controlled substance in section 28-405, that 28 is either portrayed in such a manner by a person to lead another person 29 to reasonably believe that it produces effects on the human body that 30 replicate, mimic, or are intended to simulate the effects produced by a 31 controlled substance or that possesses one or more of the following

-14-

1 indicia

indicia or characteristics:

2 (a) The packaging or labeling of the product or substance suggests
3 that the user will achieve euphoria, hallucination, mood enhancement,
4 stimulation, or another effect on the human body that replicates or
5 mimics those produced by a controlled substance;

6 (b) The name or packaging of the product or substance uses images or 7 labels suggesting that it is a controlled substance or produces effects 8 on the human body that replicate or mimic those produced by a controlled 9 substance;

10 (c) The product or substance is marketed or advertised for a 11 particular use or purpose and the cost of the product or substance is 12 disproportionately higher than other products or substances marketed or 13 advertised for the same or similar use or purpose;

(d) The packaging or label on the product or substance contains words or markings that state or suggest that the product or substance is in compliance with state and federal laws regulating controlled substances;

(e) The owner or person in control of the product or substance uses
evasive tactics or actions to avoid detection or inspection of the
product or substance by law enforcement authorities;

(f) The owner or person in control of the product or substance makes a verbal or written statement suggesting or implying that the product or substance is a synthetic drug or that consumption of the product or substance will replicate or mimic effects on the human body to those effects commonly produced through use or consumption of a controlled substance;

(g) The owner or person in control of the product or substance makes a verbal or written statement to a prospective customer, buyer, or recipient of the product or substance implying that the product or substance may be resold for profit; or

31 (h) The product or substance contains a chemical or chemical

LB22

2023

-15-

1 compound that does not have a legitimate relationship to the use or 2 purpose claimed by the seller, distributor, packer, or manufacturer of 3 the product or substance or indicated by the product name, appearing on 4 the product's packaging or label or depicted in advertisement of the 5 product or substance.

6 Sec. 5. Section 28-405, Revised Statutes Cumulative Supplement,
7 2022, is amended to read:

8 28-405 The following are the schedules of controlled substances 9 referred to in the Uniform Controlled Substances Act, unless specifically 10 contained on the list of exempted products of the Drug Enforcement 11 Administration of the United States Department of Justice as the list 12 existed on January 31, 2021:

13 Schedule I

(a) Any of the following opiates, including their isomers, esters,
ethers, salts, and salts of isomers, esters, and ethers, unless
specifically excepted, whenever the existence of such isomers, esters,
ethers, and salts is possible within the specific chemical designation:

- 18 (1) Acetylmethadol;
- 19 (2) Allylprodine;

(3) Alphacetylmethadol, except levo-alphacetylmethadol which is also
known as levo-alpha-acetylmethadol, levomethadyl acetate, and LAAM;

22 (4) Alphameprodine;

23 (5) Alphamethadol;

24 (6) Benzethidine;

- 25 (7) Betacetylmethadol;
- 26 (8) Betameprodine;
- 27 (9) Betamethadol;
- 28 (10) Betaprodine;
- 29 (11) Clonitazene;
- 30 (12) Dextromoramide;
- 31 (13) Difenoxin;

| - | | | | |
|---|----|------|-------------------------|-------------|
| | 1 | (14) | Diampromide; | |
| | 2 | (15) | Diethylthiambutene; | |
| | 3 | (16) | Dimenoxadol; | |
| | 4 | (17) | Dimepheptanol; | |
| | 5 | (18) | Dimethylthiambutene; | |
| | 6 | (19) | Dioxaphetyl butyrate; | |
| | 7 | (20) | Dipipanone; | |
| | 8 | (21) | Ethylmethylthiambutene; | |
| | 9 | (22) | Etonitazene; | |
| | 10 | (23) | Etoxeridine; | |
| | 11 | (24) | Furethidine; | |
| | 12 | (25) | Hydroxypethidine; | |
| | 13 | (26) | Ketobemidone; | |
| | 14 | (27) | Levomoramide; | |
| | 15 | (28) | Levophenacylmorphan; | |
| | 16 | (29) | Morpheridine; | |
| | 17 | (30) | Noracymethadol; | |
| | 18 | (31) | Norlevorphanol; | |
| | 19 | (32) | Normethadone; | |
| | 20 | (33) | Norpipanone; | |
| | 21 | (34) | Phenadoxone; | |
| | 22 | (35) | Phenampromide; | |
| | 23 | (36) | Phenomorphan; | |
| | 24 | (37) | Phenoperidine; | |
| | 25 | (38) | Piritramide; | |
| | 26 | (39) | Proheptazine; | |
| | 27 | (40) | Properidine; | |
| | 28 | (41) | Propiram; | |
| | 29 | (42) | Racemoramide; | |
| | 30 | (43) | Trimeperidine; | |
| | 31 | (44) | Alpha-methylfentanyl, | N-(1-(alpha |
| | | | | |

(44) Alpha-methylfentanyl, N-(1-(alpha-methyl-beta-phenyl)ethyl-4-

piperidyl) propionanilide, 1-(1-methyl-2-phenylethyl)-4-(N-propanilido)
piperidine;

3 (45) Tilidine;

4 (46) 3-Methylfentanyl, N-(3-methyl-1-(2-phenylethyl)-4-piperidyl)-N5 phenylpropanamide, its optical and geometric isomers, salts, and salts of
6 isomers;

7 (47) 1-methyl-4-phenyl-4-propionoxypiperidine (MPPP), its optical
8 isomers, salts, and salts of isomers;

9 (48) PEPAP, 1-(2-phenethyl)-4-phenyl-4-acetoxypiperidine, its 10 optical isomers, salts, and salts of isomers;

11 (49) Acetyl-alpha-methylfentanyl, N-(1-(1-methyl-2-phenethyl)-4-12 piperidinyl)-N-phenylacetamide, its optical isomers, salts, and salts of 13 isomers;

14 (50) Alpha-methylthiofentanyl, N-(1-methyl-2-(2-thienyl)ethyl-415 piperidinyl)-N-phenylpropanamide, its optical isomers, salts, and salts
16 of isomers;

17 (51) Benzylfentanyl, N-(1-benzyl-4-piperidyl)-N-phenylpropanamide,
18 its optical isomers, salts, and salts of isomers;

19 (52) Beta-hydroxyfentanyl, N-(1-(2-hydroxy-2-phenethyl)-4 20 piperidinyl)-N-phenylpropanamide, its optical isomers, salts, and salts
 21 of isomers;

(53) Beta-hydroxy-3-methylfentanyl, (other name: N-(1-(2-hydroxy-2phenethyl)-3-methyl-4-piperidinyl)-N-phenylpropanamide), its optical and
geometric isomers, salts, and salts of isomers;

(54) 3-methylthiofentanyl, N-(3-methyl-1-(2-thienyl)ethyl-4piperidinyl)-N-phenylpropanamide, its optical and geometric isomers,
salts, and salts of isomers;

(55) N-(1-(2-thienyl)methyl-4-piperidyl)-N-phenylpropanamide
(thenylfentanyl), its optical isomers, salts, and salts of isomers;

30 (56) Thiofentanyl, N-phenyl-N-(1-(2-thienyl)ethyl-4-piperidinyl)31 propanamide, its optical isomers, salts, and salts of isomers;

-18-

| LB22 2023 | LB22 2023 |
|--------------|---|
| 1 | (57) Para-fluorofentanyl, N-(4-fluorophenyl)-N-(1-(2-phenethyl)-4- |
| 2 | piperidinyl)propanamide, its optical isomers, salts, and salts of |
| 3 | isomers; |
| 4 | (58) U-47700, 3,4-dichloro-N-[2-(dimethylamino)cyclohexyl]-N- |
| 5 | methylbenzamide; |
| 6 | (59) 4-Fluoroisobutyryl Fentanyl; |
| 7 | (60) Acetyl Fentanyl; |
| 8 | (61) Acyrloylfentanyl; |
| 9 | <pre>(62) AH-7921; 3, 4-dichloro-N-[(1-dimethylamino) cyclohexylmethyl]</pre> |
| 10 | benzamide; |
| 11 | (63) Butyryl fentanyl; |
| 12 | (64) Cyclopentyl fentanyl; |
| 13 | (65) Cyclopropyl fentanyl; |
| 14 | (66) Furanyl fentanyl; |
| 15 | (67) Isobutyryl fentanyl; |
| 16 | (68) Isotonitazene; |
| 17 | (69) Methoxyacetyl fentanyl; |
| 18 | <pre>(70) MT-45; 1-cyclohexyl-4-(1,2-diphenylethyl) piperazine;</pre> |
| 19 | (71) Tetrahydrofuranyl fentanyl; |
| 20 | (72) 2-fluorofentanyl; N-(2-fluorophenyl)-N-(1-phenethylpiperidin-4- |
| 21 | yl) propionamide; |
| 22 | (73) Ocfentanil; |
| 23 | (74) Ortho-Fluorofentanyl; |
| 24 | (75) Para-chloroisobutyryl fentanyl; |
| 25 | (76) Para-Fluorobutyryl Fentanyl; |
| 26 | (77) Valeryl fentanyl; |
| 27 | (78) Phenyl Fentanyl; |
| 28 | (79) Para-Methylfentanyl; |
| 29 | (80) Thiofuranyl Fentanyl; |
| 30 | (81) Beta-methyl Fentanyl; |
| 31 | (82) Beta'-Phenyl Fentanyl; |

| LB22 2023 | LB22 2023 |
|--------------|---|
| 1 | (83) Crotonyl Fentanyl; |
| 2 | (84) 2'-Fluoro Ortho-Fluorofentanyl; |
| 3 | (85) 4'-Methyl Acetyl Fentanyl; |
| 4 | (86) Ortho-Fluorobutyryl Fentanyl; |
| 5 | (87) Ortho-Methyl Acetylfentanyl; |
| 6 | (88) Ortho-Methyl Methoxyacetyl Fentanyl; |
| 7 | (89) Ortho-Fluoroacryl Fentanyl; |
| 8 | (90) Fentanyl Carbamate; |
| 9 | (91) Ortho-Fluoroisobutyryl Fentanyl; |
| 10 | (92) Para-Fluoro Furanyl Fentanyl; |
| 11 | (93) Para-Methoxybutyryl Fentanyl; and |
| 12 | (94) Brorphine (other name: 1-(1-(1-(4-bromophenyl) ethyl) |
| 13 | piperidin-4-yl-1,3-dihydro-2H-benzo[D]imidazole-2-one). |
| 14 | (b) Any of the following opium derivatives, their salts, isomers, |
| 15 | and salts of isomers, unless specifically excepted, whenever the |
| 16 | existence of such salts, isomers, and salts of isomers is possible within |
| 17 | the specific chemical designation: |
| 18 | <pre>(1) Acetorphine;</pre> |
| 19 | <pre>(2) Acetyldihydrocodeine;</pre> |
| 20 | <pre>(3) Benzylmorphine;</pre> |
| 21 | (4) Codeine methylbromide; |
| 22 | (5) Codeine-N-Oxide; |
| 23 | (6) Cyprenorphine; |
| 24 | (7) Desomorphine; |
| 25 | <pre>(8) Dihydromorphine;</pre> |
| 26 | (9) Drotebanol; |
| 27 | (10) Etorphine, except hydrochloride salt; |
| 28 | (11) Heroin; |
| 29 | (12) Hydromorphinol; |
| 30 | <pre>(13) Methyldesorphine;</pre> |
| 31 | <pre>(14) Methyldihydromorphine;</pre> |

| LB22 2023 | |
|--------------|--|
| 1 | (15) Morphine methylbromide; |
| 2 | <pre>(16) Morphine methylsulfonate;</pre> |
| 3 | (17) Morphine-N-Oxide; |
| 4 | (18) Myrophine; |
| 5 | (19) Nicocodeine; |
| 6 | (20) Nicomorphine; |
| 7 | (21) Normorphine; |
| 8 | (22) Pholcodine; and |
| 9 | (23) Thebacon. |
| 10 | (a) Any meterial compound mixture or propagation which con |

LB22 2023

10 (c) Any material, compound, mixture, or preparation which contains 11 any quantity of the following hallucinogenic substances, their salts, 12 isomers, and salts of isomers, unless specifically excepted, whenever the 13 existence of such salts, isomers, and salts of isomers is possible within 14 the specific chemical designation, and, for purposes of this subdivision 15 only, isomer shall include the optical, position, and geometric isomers:

(1) Bufotenine. Trade and other names shall include, but are not
limited to: 3-(beta-Dimethylaminoethyl)-5-hydroxyindole; 3-(2dimethylaminoethyl)-5-indolol; N,N-dimethylserotonin; 5-hydroxy-N,Ndimethyltryptamine; and mappine;

(2) 4-bromo-2,5-dimethoxyamphetamine. Trade and other names shall
include, but are not limited to: 4-bromo-2,5-dimethoxy-alphamethylphenethylamine; and 4-bromo-2,5-DMA;

(3) 4-methoxyamphetamine. Trade and other names shall include, but
are not limited to: 4-methoxy-alpha-methylphenethylamine; and
paramethoxyamphetamine, PMA;

(4) 4-methyl-2,5-dimethoxyamphetamine. Trade and other names shall
include, but are not limited to: 4-methyl-2,5-dimethoxy-alphamethylphenethylamine; DOM; and STP;

(5) Para-methoxymethamphetamine. Trade and other names shall
include, but are not limited to: 1-(4-Methoxyphenyl)-N-methylpropan-2amine, PMMA, and 4-MMA;

-21-

(6) Ibogaine. Trade and other names shall include, but are not
 limited to: 7-Ethyl-6,6beta,7,8,9,10,12,13-octahydro-2-methoxy-6,9 methano-5H-pyrido (1',2':1,2) azepino (5,4-b) indole; and Tabernanthe
 iboga;

5 (7) Lysergic acid diethylamide;

6 (8) Marijuana;

7 (9) Mescaline;

8 (10) Peyote. Peyote shall mean all parts of the plant presently 9 classified botanically as Lophophora williamsii Lemaire, whether growing 10 or not, the seeds thereof, any extract from any part of such plant, and 11 every compound, manufacture, salts, derivative, mixture, or preparation 12 of such plant or its seeds or extracts;

13 (11) Psilocybin;

14 (12) Psilocyn;

Synthetic tetrahydrocannabinols 15 (13)Tetrahydrocannabinols, including, but not limited to, synthetic equivalents of the substances 16 17 contained in the plant or in the resinous extractives of cannabis, sp. or synthetic substances, derivatives, and their isomers with similar 18 19 chemical structure and pharmacological activity such as the following: Delta 1 cis or trans tetrahydrocannabinol and their optical isomers, 20 excluding dronabinol in a drug product approved by the federal Food and 21 Drug Administration; Delta 6 cis or trans tetrahydrocannabinol and their 22 23 optical isomers; and Delta 3,4 cis or trans tetrahydrocannabinol and its 24 optical isomers. Since nomenclature of these substances is not internationally standardized, compounds of these structures shall be 25 included regardless of the numerical designation of atomic positions 26 covered. Tetrahydrocannabinols does not include cannabidiol contained in 27 28 a drug product approved by the federal Food and Drug Administration or naturally occurring tetrahydrocannabinols extracted or derived from 29 marijuana; 30

31 (14) N-ethyl-3-piperidyl benzilate;

-22-

2

3

4

5

6

7

8

9

10

12

13

14

15

16

17

18

19

20

21

22

23

24

25

26

27

28

29

1 (15) N-methyl-3-piperidyl benzilate; (16) Thiophene analog of phencyclidine. Trade and other names shall include, but are not limited to: 1-(1-(2-thienyl)-cyclohexyl)-piperidine; 2-thienyl analog of phencyclidine; TPCP; and TCP; (17) Hashish or concentrated cannabis; (17) (18) Parahexyl. Trade and other names shall include, but are not limited to: 3-Hexyl-1-hydroxy-7,8,9,10-tetrahydro-6,6,9-trimethyl-6Hdibenzo(b,d)pyran; and Synhexyl; (18) (19) Ethylamine analog of phencyclidine. Trade and other names shall include, but are not limited to: N-ethyl-1-phenylcyclohexylamine; 11 (1-phenylcyclohexyl)ethylamine; N-(1-phenylcyclohexyl)ethylamine; cyclohexamine; and PCE; (19) (20) Pyrrolidine analog of phencyclidine. Trade and other names shall include, are not limited to: 1-(1-phenylcyclohexyl)but pyrrolidine; PCPy; and PHP; (20) (21) Alpha-ethyltryptamine. Some trade or other names: etryptamine; Monase; alpha-ethyl-1H-indole-3-ethanamine; 3-(2-aminobutyl) indole; alpha-ET; and AET; (21) (22) 2,5-dimethoxy-4-ethylamphet-amine; and DOET; (22) (23) 1-(1-(2-thienyl)cyclohexyl)pyrrolidine; and TCPy; (23) (24) Alpha-methyltryptamine, which is also known as AMT; (24) (25) Salvia divinorum or Salvinorin A. Salvia divinorum or Salvinorin A includes all parts of the plant presently classified botanically as Salvia divinorum, whether growing or not, the seeds thereof, any extract from any part of such plant, and every compound, manufacture, derivative, mixture, or preparation of such plant, its seeds, or its extracts, including salts, isomers, and salts of isomers whenever the existence of such salts, isomers, and salts of isomers is possible within the specific chemical designation;

(25) (26) Any material, compound, mixture, or preparation containing 30 any quantity of synthetically produced cannabinoids as listed in 31

-23-

1 subdivisions (A) through (L) of this subdivision, including their salts, 2 isomers, salts of isomers, and nitrogen, oxygen, or sulfur-heterocyclic analogs, unless specifically excepted elsewhere in this section. Since 3 4 nomenclature of these synthetically produced cannabinoids is not internationally standardized and may continually evolve, these structures 5 these structures shall be included under this 6 compounds of or 7 subdivision, regardless of their specific numerical designation of atomic positions covered, so long as it can be determined through a recognized 8 9 method of scientific testing or analysis that the substance contains properties that fit within one or more of the following categories: 10

11 Tetrahydrocannabinols: Meaning synthetic equivalents of (A) tetrahydrocannabinols naturally contained in a plant of the genus 12 cannabis (cannabis plant), as well as synthetic equivalents of the 13 substances contained in the plant, or in the resinous extractives of 14 cannabis, sp. and/or synthetic substances, derivatives, and their isomers 15 16 with similar chemical structure and pharmacological activity such as the following: Delta 1 cis or trans tetrahydrocannabinol, and their optical 17 isomers; Delta 6 cis or trans tetrahydrocannabinol, and their optical 18 isomers; Delta 3,4 cis or trans tetrahydrocannabinol, and its optical 19 isomers. This subdivision does not include cannabidiol contained in a 20 drug product approved by the federal Food and Drug Administration; 21

22 (B) Naphthoylindoles: Any compound containing 3-(1а 23 naphthoyl)indole structure with substitution at the nitrogen atom of the 24 indole ring by an alkyl, haloalkyl, alkenyl, halobenzyl, benzyl, 25 cycloalkylmethyl, cycloalkylethyl, 2-(4-morpholinyl)ethyl group, cyanoalkyl, 1-(N-methyl-2-piperidinyl)methyl, 1-(N-methyl-2-26 pyrrolidinyl)methyl, 27 1-(N-methyl-3-morpholinyl)methyl, or 28 tetrahydropyranylmethyl group, whether or not further substituted in or on any of the listed ring systems to any extent; 29

30 (C) Naphthylmethylindoles: Any compound containing a 1 H-indol-3 31 yl-(1-naphthyl)methane structure with substitution at the nitrogen atom

-24-

1 of the indole ring by an alkyl, haloalkyl, alkenyl, halobenzyl, benzyl, 2 cycloalkylmethyl, cycloalkylethyl, 2-(4-morpholinyl)ethyl group, 3 1-(N-methyl-2-piperidinyl)methyl, 1-(N-methyl-2cyanoalkyl, 4 pyrrolidinyl)methyl, 1-(N-methyl-3-morpholinyl)methyl, or tetrahydropyranylmethyl group, whether or not further substituted in or 5 6 on any of the listed ring systems to any extent;

7 (D) Naphthoylpyrroles: Any compound containing 3-(1а naphthoyl)pyrrole structure with substitution at the nitrogen atom of the 8 9 pyrrole ring by an alkyl, haloalkyl, alkenyl, halobenzyl, benzyl, 10 cycloalkylmethyl, cycloalkylethyl, 2-(4-morpholinyl)ethyl group, 11 cyanoalkyl, 1-(N-methyl-2-piperidinyl)methyl, 1-(N-methyl-2pyrrolidinyl)methyl, 1-(N-methyl-3-morpholinyl)methyl, 12 or tetrahydropyranylmethyl group, whether or not further substituted in or 13 14 on any of the listed ring systems to any extent;

Naphthylideneindenes: 15 (E) Any compound containing а 16 naphthylideneindene structure with substitution at the 3-position of the 17 indene ring by an alkyl, haloalkyl, alkenyl, halobenzyl, benzyl, cycloalkylmethyl, cycloalkylethyl, 2-(4-morpholinyl)ethyl 18 group, cyanoalkyl, 1-(N-methyl-2-piperidinyl)methyl, 19 1-(N-methyl-2pyrrolidinyl)methyl, 1-(N-methyl-3-morpholinyl)methyl, 20 or tetrahydropyranylmethyl group, whether or not further substituted in or 21 22 on any of the listed ring systems to any extent;

23 Phenylacetylindoles: compound containing 3-(F) Any а 24 phenylacetylindole structure with substitution at the nitrogen atom of the indole ring by an alkyl, haloalkyl, alkenyl, halobenzyl, benzyl, 25 cycloalkylmethyl, cycloalkylethyl, 2-(4-morpholinyl)ethyl 26 group, 1-(N-methyl-2-piperidinyl)methyl, 1-(N-methyl-2-27 cyanoalkyl, 28 pyrrolidinyl)methyl, 1-(N-methyl-3-morpholinyl)methyl, or tetrahydropyranylmethyl group, whether or not further substituted in or 29 on any of the listed ring systems to any extent; 30

31 (G) Cyclohexylphenols: Any compound containing a 2-(3-

-25-

1 hydroxycyclohexyl)phenol structure with substitution at the 5-position of 2 the phenolic ring by an alkyl, haloalkyl, alkenyl, halobenzyl, benzyl, 3 cycloalkylmethyl, cycloalkylethyl, 2-(4-morpholinyl)ethyl group, 4 cyanoalkyl, 1-(N-methyl-2-piperidinyl)methyl, 1-(N-methyl-2-5 pyrrolidinyl)methyl, 1-(N-methyl-3-morpholinyl)methyl, or tetrahydropyranylmethyl group, whether or not substituted in or on any of 6 7 the listed ring systems to any extent;

8 (H) Benzoylindoles: Any compound containing a 3-(benzoyl)indole 9 structure with substitution at the nitrogen atom of the indole ring by an 10 alkyl, haloalkyl, alkenyl, halobenzyl, benzyl, cycloalkylmethyl, cycloalkylethyl, 2-(4-morpholinyl)ethyl group, cyanoalkyl, 1-(N-methyl-2-11 piperidinyl)methyl, 1-(N-methyl-2-pyrrolidinyl)methyl, 12 1-(N-methyl-3morpholinyl)methyl, or tetrahydropyranylmethyl group, whether or not 13 further substituted in or on any of the listed ring systems to any 14 extent; 15

16 (I) Adamantoylindoles: Any compound containing a 3-adamantoylindole structure with substitution at the nitrogen atom of the indole ring by an 17 haloalkyl, cyanoalkyl, alkenyl, 18 alkyl, halobenzyl, benzyl, 19 cycloalkylmethyl, cycloalkylethyl, 1-(N-methyl-2-piperidinyl)methyl, 2-(4-morpholinyl)ethyl, 1-(N-methyl-2-pyrrolidinyl)methyl, 1-(N-methyl-3-20 morpholinyl)methyl, or tetrahydropyranylmethyl group, whether or not 21 further substituted in or on any of the listed ring systems to any 22 23 extent;

24 (J) Tetramethylcyclopropanoylindoles: Any compound containing a 3-25 tetramethylcyclopropanoylindole structure with substitution at the nitrogen atom of the indole ring by an alkyl, haloalkyl, cyanoalkyl, 26 alkenyl, halobenzyl, benzyl, cycloalkylmethyl, cycloalkylethyl, 1-(N-27 28 methyl-2-piperidinyl)methyl, 2-(4-morpholinyl)ethyl, 1-(N-methyl-2pyrrolidinyl)methyl, 1-(N-methyl-3-morpholinyl)methyl, 29 or tetrahydropyranylmethyl group, whether or not further substituted in or 30 31 on any of the listed ring systems to any extent;

-26-

1 (K) Indole carboxamides: Any compound containing a 1-indole-3carboxamide structure with substitution at the nitrogen atom of the 2 indole ring by an alkyl, haloalkyl, cyanoalkyl, alkenyl, halobenzyl, 3 4 benzyl, cycloalkylmethyl, cycloalkylethyl, 1-(N-methyl-2-5 piperidinyl)methyl, 2-(4-morpholinyl)ethyl, 1-(N-methyl-2pyrrolidinyl)methyl, 1-(N-methyl-3-morpholinyl)methyl, 6 or tetrahydropyranylmethyl group, substitution at the carboxamide group by 7 methoxy, benzyl, propionaldehyde, adamantyl, 1-naphthyl, 8 an alkyl, 9 phenyl, aminooxoalkyl group, or guinolinyl group, whether or not further substituted in or on any of the listed ring systems to any extent or to 10 11 the adamantyl, 1-mapthyl, phenyl, aminooxoalkyl, benzyl, or propionaldehyde groups to any extent; 12

(L) Indole carboxylates: Any compound containing a 1-indole-3-13 carboxylate structure with substitution at the nitrogen atom of the 14 indole ring by an alkyl, haloalkyl, cyanoalkyl, alkenyl, halobenzyl, 15 16 benzyl, cycloalkylmethyl, cycloalkylethyl, 1-(N-methyl-2-17 piperidinyl)methyl, 2-(4-morpholinyl)ethyl, 1-(N-methyl-2pyrrolidinyl)methyl, 1-(N-methyl-3-morpholinyl)methyl, 18 or tetrahydropyranylmethyl group, substitution at the carboxylate group by 19 benzyl, propionaldehyde, adamantyl, 1-naphthyl, methoxy, 20 an alkyl, phenyl, aminooxoalkyl group, or quinolinyl group, whether or not further 21 substituted in or on any of the listed ring systems to any extent or to 22 23 adamantyl, 1-mapthyl, phenyl, aminooxoalkyl, benzyl, the or 24 propionaldehyde groups to any extent; and

25 (M) Any nonnaturally occurring substance, chemical compound, mixture, or preparation, not specifically listed elsewhere in these 26 schedules and which is not approved for human consumption by the federal 27 Food and Drug Administration, containing or constituting a cannabinoid 28 receptor agonist as defined in section 28-401. This subdivision (M) does 29 not apply to any product or preparation containing solely 30 31 tetrahydrocannabinols which are naturally occurring and extracted or

-27-

1 <u>derived from marijuana;</u>

(26) (27) Any material, compound, mixture, or preparation containing 2 3 any quantity of a substituted phenethylamine as listed in subdivisions (A) through (C) of this subdivision, unless specifically excepted, listed 4 in another schedule, or specifically named in this schedule, that is 5 structurally derived from phenylethan-2-amine by substitution on the 6 7 phenyl ring with a fused methylenedioxy ring, fused furan ring, or a 8 fused tetrahydrofuran ring; by substitution with two alkoxy groups; by substitution with one alkoxy and either one fused furan, tetrahydrofuran, 9 or tetrahydropyran ring system; or by substitution with two fused ring 10 11 systems from any combination of the furan, tetrahydrofuran, or tetrahydropyran ring systems, whether or not the compound is further 12 13 modified in any of the following ways:

(A) Substitution of the phenyl ring by any halo, hydroxyl, alkyl,
trifluoromethyl, alkoxy, or alkylthio groups; (B) substitution at the 2position by any alkyl groups; or (C) substitution at the 2-amino nitrogen
atom with alkyl, dialkyl, benzyl, hydroxybenzyl or methoxybenzyl groups,
and including, but not limited to:

(i) 2-(4-Chloro-2,5-dimethoxyphenyl)ethanamine, which is also known
as 2C-C or 2,5-Dimethoxy-4-chlorophenethylamine;

(ii) 2-(2,5-Dimethoxy-4-methylphenyl)ethanamine, which is also known as 2C-D or 2,5-Dimethoxy-4-methylphenethylamine;

23 (iii) 2-(2,5-Dimethoxy-4-ethylphenyl)ethanamine, which is also known
24 as 2C-E or 2,5-Dimethoxy-4-ethylphenethylamine;

(iv) 2-(2,5-Dimethoxyphenyl)ethanamine, which is also known as 2C-H
or 2,5-Dimethoxyphenethylamine;

27 (v) 2-(4-lodo-2,5-dimethoxyphenyl)ethanamine, which is also known as
28 2C-I or 2,5-Dimethoxy-4-iodophenethylamine;

(vi) 2-(2,5-Dimethoxy-4-nitro-phenyl)ethanamine, which is also known
as 2C-N or 2,5-Dimethoxy-4-nitrophenethylamine;

31 (vii) 2-(2,5-Dimethoxy-4-(n)-propylphenyl)ethanamine, which is also

| 1 | known as 2C-P or 2,5-Dimethoxy-4-propylphenethylamine; |
|----|---|
| 2 | (viii) 2-[4-(Ethylthio)-2,5-dimethoxyphenyl]ethanamine, which is |
| 3 | also known as 2C-T-2 or 2,5-Dimethoxy-4-ethylthiophenethylamine; |
| 4 | (ix) 2-[4-(Isopropylthio)-2,5-dimethoxyphenyl]ethanamine, which is |
| 5 | also known as 2C-T-4 or 2,5-Dimethoxy-4-isopropylthiophenethylamine; |
| 6 | (x) 2-(4-bromo-2,5-dimethoxyphenyl)ethanamine, which is also known |
| 7 | as 2C-B or 2,5-Dimethoxy-4-bromophenethylamine; |
| 8 | (xi) 2-(2,5-dimethoxy-4-(methylthio)phenyl)ethanamine, which is also |
| 9 | known as 2C-T or 4-methylthio-2,5-dimethoxyphenethylamine; |
| 10 | (xii) 1-(2,5-dimethoxy-4-iodophenyl)-propan-2-amine, which is also |
| 11 | known as DOI or 2,5-Dimethoxy-4-iodoamphetamine; |
| 12 | (xiii) 1-(4-Bromo-2,5-dimethoxyphenyl)-2-aminopropane, which is also |
| 13 | known as DOB or 2,5-Dimethoxy-4-bromoamphetamine; |
| 14 | (xiv) 1-(4-chloro-2,5-dimethoxy-phenyl)propan-2-amine, which is also |
| 15 | known as DOC or 2,5-Dimethoxy-4-chloroamphetamine; |
| 16 | (xv) 2-(4-bromo-2,5-dimethoxyphenyl)-N-[(2- |
| 17 | methoxyphenyl)methyl]ethanamine, which is also known as 2C-B-NBOMe; 25B- |
| 18 | NBOMe or 2,5-Dimethoxy-4-bromo-N-(2-methoxybenzyl)phenethylamine; |
| 19 | (xvi) 2-(4-iodo-2,5-dimethoxyphenyl)-N-[(2- |
| 20 | methoxyphenyl)methyl]ethanamine, which is also known as 2C-I-NBOMe; 25I- |
| 21 | NBOMe or 2,5-Dimethoxy-4-iodo-N-(2-methoxybenzyl)phenethylamine; |
| 22 | <pre>(xvii) N-(2-Methoxybenzyl)-2-(3,4,5-trimethoxyphenyl)ethanamine,</pre> |
| 23 | which is also known as Mescaline-NBOMe or 3,4,5-trimethoxy-N-(2- |
| 24 | <pre>methoxybenzyl)phenethylamine;</pre> |
| 25 | (xviii) 2-(4-chloro-2,5-dimethoxyphenyl)-N-[(2- |
| 26 | methoxyphenyl)methyl]ethanamine, which is also known as 2C-C-NBOMe; or |
| 27 | 25C-NBOMe or 2,5-Dimethoxy-4-chloro-N-(2-methoxybenzyl)phenethylamine; |
| 28 | <pre>(xix) 2-(7-Bromo-5-methoxy-2,3-dihydro-1-benzofuran-4-yl)ethanamine,</pre> |
| 29 | which is also known as 2CB-5-hemiFLY; |
| 30 | (xx) 2-(8-bromo-2,3,6,7-tetrahydrofuro [2,3-f][1]benzofuran-4- |
| 31 | yl)ethanamine, which is also known as 2C-B-FLY; |

-29-

| LB22 2023 | LB22 2023 |
|--------------|--|
| 1 | (xxi) 2-(10-Bromo-2,3,4,7,8,9-hexahydropyrano[2,3-g]chromen-5- |
| 2 | yl)ethanamine, which is also known as 2C-B-butterFLY; |
| 3 | <pre>(xxii) N-(2-Methoxybenzyl)-1-(8-bromo-2,3,6,7- tetrahydrobenzo[1,2-</pre> |
| 4 | b:4,5-b']difuran-4-yl)-2-aminoethane, which is also known as 2C-B-FLY- |
| 5 | NBOMe; |
| 6 | <pre>(xxiii) 1-(4-Bromofuro[2,3-f][1]benzofuran-8-yl)propan-2-amine,</pre> |
| 7 | which is also known as bromo-benzodifuranylisopropylamine or bromo- |
| 8 | dragonFLY; |
| 9 | (xxiv) N-(2-Hydroxybenzyl)-4-iodo-2,5-dimethoxyphenethylamine, which |
| 10 | is also known as 2C-INBOH or 25I-NBOH; |
| 11 | (xxv) 5-(2-Aminopropyl)benzofuran, which is also known as 5-APB; |
| 12 | (xxvi) 6-(2-Aminopropyl)benzofuran, which is also known as 6-APB; |
| 13 | (xxvii) 5-(2-Aminopropyl)-2,3-dihydrobenzofuran, which is also known |
| 14 | as 5-APDB; |
| 15 | (xxviii) 6-(2-Aminopropyl)-2,3-dihydrobenzofuran, which is also |
| 16 | known as 6-APDB; |
| 17 | (xxix) 2,5-dimethoxy-amphetamine, which is also known as 2, 5- |
| 18 | dimethoxy-a-methylphenethylamine; 2, 5-DMA; |
| 19 | (xxx) 2,5-dimethoxy-4-ethylamphetamine, which is also known as DOET; |
| 20 | (xxxi) 2,5-dimethoxy-4-(n)-propylthiophenethylamine, which is also |
| 21 | known as 2C-T-7; |
| 22 | <pre>(xxxii) 5-methoxy-3,4-methylenedioxy-amphetamine;</pre> |
| 23 | (xxxiii) 4-methyl-2,5-dimethoxy-amphetamine, which is also known as |
| 24 | 4-methyl-2,5-dimethoxy-amethylphenethylamine; DOM and STP; |
| 25 | (xxxiv) 3,4-methylenedioxy amphetamine, which is also known as MDA; |
| 26 | (xxxv) 3,4-methylenedioxymethamphetamine, which is also known as |
| 27 | MDMA; |
| 28 | (xxxvi) 3,4-methylenedioxy-N-ethylamphetamine, which is also known |
| 29 | as N-ethyl-alpha-methyl-3,4(methylenedioxy)phenethylamine, MDE, MDEA; |
| 30 | (xxxvii) 3,4,5-trimethoxy amphetamine; and |
| 31 | (xxxviii) n-hydroxy-3.4-Methylenedioxy-N-Hydroxyamphetamine, which |

-30-

1 is also known as N-hydroxyMDA;

(27) (28) Any material, compound, mixture, or preparation containing 2 3 any quantity of a substituted tryptamine unless specifically excepted, listed in another schedule, or specifically named in this schedule, that 4 5 is structurally derived from 2-(1H-indol-3-yl)ethanamine, which is also 6 known as tryptamine, by mono- or di-substitution of the amine nitrogen 7 with alkyl or alkenyl groups or by inclusion of the amino nitrogen atom 8 in a cyclic structure whether or not the compound is further substituted 9 at the alpha position with an alkyl group or whether or not further substituted on the indole ring to any extent with any alkyl, alkoxy, 10 halo, hydroxyl, or acetoxy groups, and including, but not limited to: 11

12 (A) 5-methoxy-N,N-diallyltryptamine, which is also known as 5-MeO 13 DALT;

(B) 4-acetoxy-N,N-dimethyltryptamine, which is also known as 4-AcO DMT or OAcetylpsilocin;

16 (C) 4-hydroxy-N-methyl-N-ethyltryptamine, which is also known as 4-17 HO-MET;

(D) 4-hydroxy-N,N-diisopropyltryptamine, which is also known as 4 HO-DIPT;

(E) 5-methoxy-N-methyl-N-isopropyltryptamine, which is also known as
 5-MeOMiPT;

(F) 5-Methoxy-N,N-Dimethyltryptamine, which is also known as 5-MeO DMT;

24 (G) 5-methoxy-N,N-diisopropyltryptamine, which is also known as 5 25 MeO-DiPT;

26 (H) Diethyltryptamine, which is also known as N,N-Diethyltryptamine,
 27 DET; and

28 (I) Dimethyltryptamine, which is also known as DMT; and

<u>(28)(A)</u> (29)(A) Any substance containing any quantity of the
 following materials, compounds, mixtures, or structures:

31 (i) 3,4-methylenedioxymethcathinone, or bk-MDMA, or methylone;

-31-

1

(ii) 3,4-methylenedioxypyrovalerone, or MDPV;

2 (iii) 4-methylmethcathinone, or 4-MMC, or mephedrone;

3 (iv) 4-methoxymethcathinone, or bk-PMMA, or PMMC, or methedrone;

LB22

2023

4 (v) Fluoromethcathinone, or FMC;

5 (vi) Naphthylpyrovalerone, or naphyrone; or

6 (vii) Beta-keto-N-methylbenzodioxolylpropylamine or bk-MBDB or
7 butylone; or

8 (B) Unless listed in another schedule, any substance which contains 9 any quantity of any material, compound, mixture, or structure, other than 10 bupropion, that is structurally derived by any means from 2aminopropan-1-one by substitution at the 1-position with either phenyl, 11 naphthyl, or thiophene ring systems, whether or not the compound is 12 further modified in any of the following ways: 13

(i) Substitution in the ring system to any extent with alkyl,
alkoxy, alkylenedioxy, haloalkyl, hydroxyl, or halide substituents,
whether or not further substituted in the ring system by one or more
other univalent substituents;

18 (ii) Substitution at the 3-position with an acyclic alkyl 19 substituent; or

(iii) Substitution at the 2-amino nitrogen atom with alkyl or
dialkyl groups, or by inclusion of the 2-amino nitrogen atom in a cyclic
structure.

(d) Unless specifically excepted or unless listed in another schedule, any material, compound, mixture, or preparation which contains any quantity of the following substances having a depressant effect on the central nervous system, including its salts, isomers, and salts of isomers whenever the existence of such salts, isomers, and salts of isomers is possible within the specific chemical designation:

29 (1) Mecloqualone;

30 (2) Methaqualone; and

31 (3) Gamma-Hydroxybutyric Acid. Some other names include: GHB; Gamma-

-32-

hydroxybutyrate; 4-Hydroxybutyrate; 4-Hydroxybutanoic Acid; Sodium
 0xybate; and Sodium 0xybutyrate.

3 (e) Unless specifically excepted or unless listed in another 4 schedule, any material, compound, mixture, or preparation which contains 5 any quantity of the following substances having a stimulant effect on the 6 central nervous system, including its salts, isomers, and salts of 7 isomers:

8

(1) Fenethylline;

9 (2) N-ethylamphetamine;

10 (3) Aminorex; aminoxaphen; 2-amino-5-phenyl-2-oxazoline; or 4,5 11 dihydro-5-phenyl-2-oxazolamine;

12 (4) Cathinone; 2-amino-1-phenyl-1-propanone; alpha13 aminopropiophenone; 2-aminopropiophenone; and norephedrone;

(5) Methcathinone, its salts, optical isomers, and salts of optical 14 isomers. 15 Some other names: 2-(methylamino)-propiophenone; alpha-(methylamino)propiophenone; 2-(methylamino)-1-phenylpropan-1-one; alpha-16 17 N-methylaminopropiophenone; methylcathinone; monomethylpropion; ephedrone; N-methylcathinone; AL-464; AL-422; AL-463; UR1432; and 4-MEC; 18

19 (6) (+/-)cis-4-methylaminorex; and (+/-)cis-4,5-dihydro-4-methyl-5-20 phenyl-2-oxazolamine;

(7) N,N-dimethylamphetamine; N,N-alpha-trimethyl-benzeneethanamine;
 and N,N-alpha-trimethylphenethylamine;

23

(8) Benzylpiperazine, 1-benzylpiperazine; and

(9) 4,4'-dimethylaminorex (other names: 4,4'-DMAR, 4,5-dihydro-4methyl-5-(4-methylphenyl)-2-oxazolamine).

26 (f) Any controlled substance analogue to the extent intended for 27 human consumption.

28 Schedule II

(a) Any of the following substances except those narcotic drugs
listed in other schedules whether produced directly or indirectly by
extraction from substances of vegetable origin, independently by means of

-33-

| LB22 2023 | LB22 2023 |
|--------------|---|
| 1 | chemical synthesis, or by combination of extraction and chemical |
| 2 | synthesis: |
| 3 | (1) Opium and opiate, and any salt, compound, derivative, or |
| 4 | preparation of opium or opiate, excluding apomorphine, buprenorphine, |
| 5 | thebaine-derived butorphanol, dextrorphan, nalbuphine, nalmefene, |
| 6 | naloxone, and naltrexone and their salts, but including the following: |
| 7 | (A) Raw opium; |
| 8 | (B) Opium extracts; |
| 9 | (C) Opium fluid; |
| 10 | (D) Powdered opium; |
| 11 | (E) Granulated opium; |
| 12 | (F) Tincture of opium; |
| 13 | (G) Codeine; |
| 14 | (H) Ethylmorphine; |
| 15 | (I) Etorphine hydrochloride; |
| 16 | (J) Hydrocodone; |
| 17 | (K) Hydromorphone; |
| 18 | (L) Metopon; |
| 19 | (M) Morphine; |
| 20 | (N) Oxycodone; |
| 21 | (O) Oxymorphone; |
| 22 | (P) Oripavine; |
| 23 | (Q) Thebaine; and |
| 24 | (R) Dihydroetorphine; |
| 25 | (2) Any salt, compound, derivative, or preparation thereof which is |
| 26 | chemically equivalent to or identical with any of the substances referred |
| 27 | to in subdivision (1) of this subdivision, except that these substances |
| 28 | shall not include the isoquinoline alkaloids of opium; |
| 29 | (3) Opium poppy and poppy straw; |
| 30 | (4) Coca leaves and any salt, compound, derivative, or preparation |

31 of coca leaves, and any salt, compound, derivative, or preparation

-34-

thereof which is chemically equivalent to or identical with any of these substances, including cocaine or ecgonine and its salts, optical isomers, and salts of optical isomers, except that the substances shall not include decocainized coca leaves or extractions which do not contain cocaine or ecgonine; and

6 (5) Concentrate of poppy straw, the crude extract of poppy straw in 7 either liquid, solid, or powder form which contains the phenanthrene 8 alkaloids of the opium poppy.

9 (b) Unless specifically excepted or unless in another schedule any 10 of the following opiates, including their isomers, esters, ethers, salts, 11 and salts of their isomers, esters, and ethers whenever the existence of 12 such isomers, esters, ethers, and salts is possible within the specific 13 chemical designation, dextrorphan excepted:

- 14 (1) Alphaprodine;
- 15 (2) Anileridine;
- 16 (3) Bezitramide;
- 17 (4) Diphenoxylate;
- 18 (5) Fentanyl;
- 19 (6) Isomethadone;
- 20 (7) Levomethorphan;
- 21 (8) Levorphanol;
- 22 (9) Metazocine;
- 23 (10) Methadone;

24 (11) Methadone-intermediate, 4-cyano-2-dimethylamino-4,4-diphenyl

- 25 butane;
- 26 (12) Moramide-intermediate, 2-methyl-3-morpholino-1,1-
- 27 diphenylpropane-carboxylic acid;
- 28 (13) Norfentanyl (N-phenyl-N-piperidin-4-yl) propionamide;
- 29 (14) Oliceridine;
- 30 (15) Pethidine or meperidine;
- 31 (16) Pethidine-Intermediate-A, 4-cyano-1-methyl-4-phenylpiperidine;

| LB22 2023 | LB22 2023 |
|--------------|---|
| 1 | (17) Pethidine-Intermediate-B, ethyl-4-phenylpiperidine-4- |
| 2 | carboxylate; |
| 3 | (18) Pethidine-Intermediate-C, 1-methyl-4-phenylpiperidine-4- |
| 4 | carboxylic acid; |
| 5 | (19) Phenazocine; |
| 6 | (20) Piminodine; |
| 7 | (21) Racemethorphan; |
| 8 | (22) Racemorphan; |
| 9 | (23) Dihydrocodeine; |
| 10 | (24) Bulk Propoxyphene in nondosage forms; |
| 11 | (25) Sufentanil; |
| 12 | (26) Alfentanil; |
| 13 | (27) Levo-alphacetylmethadol which is also known as levo-alpha- |
| 14 | acetylmethadol, levomethadyl acetate, and LAAM; |
| 15 | (28) Carfentanil; |
| 16 | (29) Remifentanil; |
| 17 | (30) Tapentadol; and |
| 18 | (31) Thiafentanil. |
| 19 | (c) Any material, compound, mixture, or preparation which contains |
| 20 | any quantity of the following substances having a potential for abuse |
| 21 | associated with a stimulant effect on the central nervous system: |
| 22 | (1) Amphetamine, its salts, optical isomers, and salts of its |
| 23 | optical isomers; |
| 24 | (2) Phenmetrazine and its salts; |
| 25 | (3) Methamphetamine, its salts, isomers, and salts of its isomers; |
| 26 | (4) Methylphenidate; and |
| 27 | (5) Lisdexamfetamine, its salts, isomers, and salts of its isomers. |
| 28 | (d) Any material, compound, mixture, or preparation which contains |
| 29 | any quantity of the following substances having a potential for abuse |
| 30 | associated with a depressant effect on the central nervous system, |
| 31 | including their salts, isomers, and salts of isomers whenever the |

-36-

1 existence of such salts, isomers, and salts of isomers is possible within 2 the specific chemical designations:

3 (1) Amobarbital;

4 (2) Secobarbital;

5 (3) Pentobarbital;

6 (4) Phencyclidine; and

7 (5) Glutethimide.

8 (e) Hallucinogenic substances known as:

9 (1) Nabilone. Another name for nabilone: (+/-)-trans-3-(1,110 dimethylheptyl)- 6,6a,7,8,10,10a-Hexahydro-1-hydroxy-6,6-dimethyl-9H11 dibenzo(b,d)pyran-9-one; and

(2) Dronabinol in an oral solution in a drug product approved by thefederal Food and Drug Administration.

(f) Unless specifically excepted or unless listed in another
schedule, any material, compound, mixture, or preparation which contains
any quantity of the following substances:

17 (1) Immediate precursor to amphetamine and methamphetamine:
18 Phenylacetone. Trade and other names shall include, but are not limited
19 to: Phenyl-2-propanone; P2P; benzyl methyl ketone; and methyl benzyl
20 ketone;

21 (2) Immediate precursors to phencyclidine, PCP:

22 (A) 1-phenylcyclohexylamine; or

23 (B) 1-piperidinocyclohexanecarbonitrile, PCC; or

(3) Immediate precursor to fentanyl; 4-anilino-N-phenethylpiperidine(ANPP).

26 Schedule III

(a) Any material, compound, mixture, or preparation which contains
any quantity of the following substances having a potential for abuse
associated with a stimulant effect on the central nervous system,
including their salts, isomers, whether optical, position, or geometric,
and salts of such isomers whenever the existence of such salts, isomers,

1 and salts of isomers is possible within the specific chemical 2 designation:

3 (1) Benzphetamine;

4 (2) Chlorphentermine;

5 (3) Clortermine; and

6 (4) Phendimetrazine.

7 (b) Any material, compound, mixture, or preparation which contains
8 any quantity of the following substances having a potential for abuse
9 associated with a depressant effect on the central nervous system:

(1) Any substance which contains any quantity of a derivative of
 barbituric acid or any salt of a derivative of barbituric acid, except
 those substances which are specifically listed in other schedules of this
 section;

- 14 (2) Aprobarbital;
- 15 (3) Butabarbital;
- 16 (4) Butalbital;
- 17 (5) Butethal;
- 18 (6) Butobarbital;
- 19 (7) Chlorhexadol;
- 20 (8) Embutramide;
- 21 (9) Lysergic acid;
- 22 (10) Lysergic acid amide;
- 23 (11) Methyprylon;
- 24 (12) Perampanel;
- 25 (13) Secbutabarbital;
- 26 (14) Sulfondiethylmethane;
- 27 (15) Sulfonethylmethane;
- 28 (16) Sulfonmethane;
- 29 (17) Nalorphine;
- 30 (18) Talbutal;
- 31 (19) Thiamylal;

1 (20) Thiopental;

2 (21) Vinbarbital;

3 (22) Any compound, mixture, or preparation containing amobarbital,
4 secobarbital, pentobarbital, or any salt thereof and one or more other
5 active medicinal ingredients which are not listed in any schedule;

6 (23) Any suppository dosage form containing amobarbital, 7 secobarbital, pentobarbital, or any salt of any of these drugs and 8 approved by the federal Food and Drug Administration for marketing only 9 as a suppository;

10 (24) Any drug product containing gamma-hydroxybutyric acid, 11 including its salts, isomers, and salts of isomers, for which an 12 application is approved under section 505 of the Federal Food, Drug, and 13 Cosmetic Act, 21 U.S.C. 355, as such section existed on January 1, 2014;

14 (25) Ketamine, its salts, isomers, and salts of isomers. Some other 15 names for ketamine: (+/-)-2-(2-chlorophenyl)-2-(methylamino)-16 cyclohexanone; and

17 (26) Tiletamine and zolazepam or any salt thereof. Trade or other names for a tiletamine-zolazepam combination product shall include, but 18 are not limited to: telazol. Trade or other names for tiletamine shall 19 include, limited to: 2-(ethylamino)-2-(2-thienyl)-20 but are not 21 cyclohexanone. Trade or other names for zolazepam shall include, but are 22 not limited to: 4-(2-fluorophenyl)-6,8-dihydro-1,3,8trimethylpyrazolo-(3,4-e) (1,4)-diazepin-7(1H)-one, and flupyrazapon. 23

24 (c) Unless specifically excepted or unless listed in another 25 schedule:

(1) Any material, compound, mixture, or preparation containing
limited quantities of any of the following narcotic drugs, or any salts
calculated as the free anhydrous base or alkaloid, in limited quantities
as set forth below:

30 (A) Not more than one and eight-tenths grams of codeine per one
 31 hundred milliliters or not more than ninety milligrams per dosage unit,

-39-

1 with an equal or greater quantity of an isoquinoline alkaloid of opium;

2 (B) Not more than one and eight-tenths grams of codeine per one 3 hundred milliliters or not more than ninety milligrams per dosage unit, 4 with one or more active, nonnarcotic ingredients in recognized 5 therapeutic amounts;

6 (C) Not more than one and eight-tenths grams of dihydrocodeine per 7 one hundred milliliters or not more than ninety milligrams per dosage 8 unit, with one or more active, nonnarcotic ingredients in recognized 9 therapeutic amounts;

10 (D) Not more than three hundred milligrams of ethylmorphine per one 11 hundred milliliters or not more than fifteen milligrams per dosage unit, 12 with one or more active, nonnarcotic ingredients in recognized 13 therapeutic amounts;

(E) Not more than five hundred milligrams of opium per one hundred
milliliters or per one hundred grams, or not more than twenty-five
milligrams per dosage unit, with one or more active, nonnarcotic
ingredients in recognized therapeutic amounts; and

(F) Not more than fifty milligrams of morphine per one hundred
 milliliters or per one hundred grams with one or more active, nonnarcotic
 ingredients in recognized therapeutic amounts; and

(2) Any material, compound, mixture, or preparation containing any
of the following narcotic drug or its salts, as set forth below:

23 (A) Buprenorphine.

(d) Unless contained on the list of exempt anabolic steroids of the Drug Enforcement Administration of the United States Department of Justice as the list existed on January 31, 2021, any anabolic steroid, which shall include any material, compound, mixture, or preparation containing any quantity of the following substances, including its salts, isomers, and salts of isomers whenever the existence of such salts of isomers is possible within the specific chemical designation:

31 (1) 3-beta, 17-dihydroxy-5a-androstane;

-40-

| LB22 2023 | LB22 2023 | |
|--------------|---|--|
| 1 | <pre>(2) 3-alpha,17-beta-dihydroxy-5a-androstane;</pre> | |
| 2 | <pre>(3) 5-alpha-androstan-3,17-dione;</pre> | |
| 3 | (4) 1-androstenediol (3-beta,17-beta-dihydroxy-5-alpha-androst-1- | |
| 4 | ene); | |
| 5 | (5) 1-androstenediol (3-alpha,17-beta-dihydroxy-5-alpha-androst-1- | |
| 6 | ene); | |
| 7 | <pre>(6) 4-androstenediol (3-beta,17-beta-dihydroxy-androst-5-ene);</pre> | |
| 8 | <pre>(7) 5-androstenediol (3-beta,17-beta-dihydroxy-androst-5-ene);</pre> | |
| 9 | <pre>(8) 1-androstenedione ([5-alpha]-androst-1-en-3,17-dione);</pre> | |
| 10 | <pre>(9) 4-androstenedione (androst-4-en-3,17-dione);</pre> | |
| 11 | <pre>(10) 5-androstenedione (androst-5-en-3,17-dione);</pre> | |
| 12 | (11) Bolasterone (7-alpha,17-alpha-dimethyl-17-beta- | |
| 13 | hydroxyandrost-4-en-3-one); | |
| 14 | <pre>(12) Boldenone (17-beta-hydroxyandrost-1,4-diene-3-one);</pre> | |
| 15 | <pre>(13) Boldione (androsta-1,4-diene-3,17-3-one);</pre> | |
| 16 | (14) Calusterone (7-beta,17-alpha-dimethyl-17-beta-hydroxyandrost-4- | |
| 17 | en-3-one); | |
| 18 | <pre>(15) Clostebol (4-chloro-17-beta-hydroxyandrost-4-en-3-one);</pre> | |
| 19 | (16) Dehydrochloromethyltestosterone (4-chloro-17-beta-hydroxy-17- | |
| 20 | <pre>alpha-methyl-androst-1,4-dien-3-one);</pre> | |
| 21 | (17) Desoxymethyltestosterone (17-alpha-methyl-5-alpha-androst-2- | |
| 22 | en-17-beta-ol) (a.k.a. 'madol'); | |
| 23 | (18) Delta-1-Dihydrotestosterone (a.k.a. '1-testosterone')(17-beta- | |
| 24 | hydroxy-5-alpha-androst-1-en-3-one); | |
| 25 | <pre>(19) 4-Dihydrotestosterone (17-beta-hydroxy-androstan-3-one);</pre> | |
| 26 | (20) Drostanolone (17-beta-hydroxy-2-alpha-methyl-5-alpha- | |
| 27 | androstan-3-one); | |
| 28 | <pre>(21) Ethylestrenol (17-alpha-ethyl-17-beta-hydroxyestr-4-ene);</pre> | |
| 29 | (22) Fluoxymesterone (9-fluoro-17-alpha-methyl-11-beta,17-beta- | |
| 30 | dihydroxyandrost-4-en-3-one); | |
| 31 | (23) Formebulone (formebolone); (2-formyl-17-alpha-methyl-11- | |

-41-

| 2023 | | 2023 |
|------|----------------------------|--|
| 1 | alpha,17-beta-dihydro | xyandrost-1,4-dien-3-one); |
| 2 | (24) Furazabol | (17-alpha-methyl-17-beta-hydroxyandrostano[2,3-c]- |
| 3 | furazan); | |
| 4 | (25) 13-beta-eth | yl-17-beta-hydroxygon-4-en-3-one; |
| 5 | (26) 4-hydroxyte | stosterone (4,17-beta-dihydroxy-androst-4-en-3-one); |
| 6 | (27) 4-hydroxy-1 | 19-nortestosterone (4,17-beta-dihydroxy-estr-4-en-3- |
| 7 | one); | |
| 8 | (28) Mestanolo | ne (17-alpha-methyl-17-beta-hydroxy-5-androstan-3- |
| 9 | one); | |
| 10 | (29) Mesterolo | ne (17-alpha-methyl-17-beta-hydroxy-5-androstan-3- |
| 11 | one); | |
| 12 | (30) Methandie | enone (17-alpha-methyl-17-beta-hydroxyandrost-1,4- |
| 13 | dien-3-one); | |
| 14 | (31) Methandriol | (17-alpha-methyl-3-beta,17-beta-dihydroxyandrost-5- |
| 15 | ene); | |
| 16 | (32) Methastero | ne (2-alpha,17-alpha-dimethyl-5-alpha-androstan-17- |
| 17 | <pre>beta-ol-3-one);</pre> | |
| 18 | (33) Methenolon | e (1-methyl-17-beta-hydroxy-5-alpha-androst-1-en-3- |
| 19 | one); | |
| 20 | (34) 17-alpha-me | thyl-3-beta,17-beta-dihydroxy-5a-androstane; |
| 21 | (35) 17-alpha-me | thyl-3-alpha,17-beta-dihydroxy-5a-androstane; |
| 22 | (36) 17-alpha-me | thyl-3-beta,17-beta-dihydroxyandrost-4-ene; |
| 23 | (37) 17-alph | a-methyl-4-hydroxynandrolone (17-alpha-methyl-4- |
| 24 | hydroxy-17-beta-hydro | xyestr-4-en-3-one); |
| 25 | (38) Methyldiend | olone (17-alpha-methyl-17-beta-hydroxyestra-4,9(10)- |
| 26 | dien-3-one); | |
| 27 | (39) Methyltrier | nolone (17-alpha-methyl-17-beta-hydroxyestra-4,9,11- |
| 28 | trien-3-one); | |
| 29 | (40) Methyltest | osterone (17-alpha-methyl-17-beta-hydroxyandrost-4- |
| 30 | en-3-one); | |
| 31 | (41) Mibolerone | e (7-alpha,17-alpha-dimethyl-17-beta-hydroxyestr-4- |

| 1 | en-3-one); | | |
|----|---|--|--|
| 2 | (42) 17-alpha-methyl-delta-1-dihydrotestosterone (17-beta- | | |
| 3 | hydroxy-17-alpha-methyl-5-alpha-androst-1-en-3-one) (a.k.a. '17-alpha- | | |
| 4 | <pre>methyl-1-testosterone');</pre> | | |
| 5 | <pre>(43) Nandrolone (17-beta-hydroxyestr-4-en-3-one);</pre> | | |
| 6 | (44) 19-nor-4-androstenediol (3-beta, 17-beta-dihydroxyestr-4-ene); | | |
| 7 | (45) 19-nor-4-androstenediol (3-alpha, 17-beta-dihydroxyestr-4-ene); | | |
| 8 | (46) 19-nor-5-androstenediol (3-beta, 17-beta-dihydroxyestr-5-ene); | | |
| 9 | (47) 19-nor-5-androstenediol (3-alpha, 17-beta-dihydroxyestr-5-ene); | | |
| 10 | (48) 19-nor-4,9(10)-androstadienedione (estra-4,9(10)-diene-3,17- | | |
| 11 | dione); | | |
| 12 | <pre>(49) 19-nor-4-androstenedione (estr-4-en-3,17-dione);</pre> | | |
| 13 | <pre>(50) 19-nor-5-androstenedione (estr-5-en-3,17-dione);</pre> | | |
| 14 | (51) Norbolethone (13-beta, 17-alpha-diethyl-17-beta-hydroxygon-4- | | |
| 15 | en-3-one); | | |
| 16 | <pre>(52) Norclostebol (4-chloro-17-beta-hydroxyestr-4-en-3-one);</pre> | | |
| 17 | (53) Norethandrolone (17-alpha-ethyl-17-beta-hydroxyestr-4-en-3- | | |
| 18 | one); | | |
| 19 | (54) Normethandrolone (17-alpha-methyl-17-beta-hydroxyestr-4-en-3- | | |
| 20 | one); | | |
| 21 | (55) Oxandrolone (17-alpha-methyl-17-beta-hydroxy-2-oxa-[5-alpha]- | | |
| 22 | androstan-3-one); | | |
| 23 | (56) Oxymesterone (17-alpha-methyl-4,17-beta-dihydroxyandrost-4- | | |
| 24 | en-3-one); | | |
| 25 | (57) Oxymetholone (17-alpha-methyl-2-hydroxymethylene-17-beta- | | |
| 26 | hydroxy-[5-alpha]-androstan-3-one); | | |
| 27 | (58) Prostanozol (17-beta-hydroxy-5-alpha-androstano[3,2- | | |
| 28 | c]pyrazole); | | |
| 29 | (59) Stanozolol (17-alpha-methyl-17-beta-hydroxy-[5-alpha]- | | |
| 30 | <pre>androst-2-eno[3,2-c]-pyrazole);</pre> | | |
| 31 | (60) Stenbolone (17-beta-hydroxy-2-methyl-[5-alpha]-androst-1-en-3- | | |

| 1 | one); |
|----|---|
| 2 | (61) Testolactone (13-hydroxy-3-oxo-13,17-secoandrosta-1,4-dien-17- |
| 3 | oic acid lactone); |
| 4 | <pre>(62) Testosterone (17-beta-hydroxyandrost-4-en-3-one);</pre> |
| 5 | (63) Tetrahydrogestrinone (13-beta, 17-alpha-diethyl-17-beta- |
| 6 | hydroxygon-4,9,11-trien-3-one); |
| 7 | <pre>(64) Trenbolone (17-beta-hydroxyestr-4,9,11-trien-3-one);</pre> |
| 8 | (65) [3,2-c]-furazan-5 alpha-androstane-17 beta-ol; |
| 9 | <pre>(66) [3,2-c]pyrazole-androst-4-en-17 beta-ol;</pre> |
| 10 | (67) 17 alpha-methyl-androst-ene-3,17 beta-diol; |
| 11 | (68) 17 alpha-methyl-androsta-1,4-diene-3,17 beta-diol; |
| 12 | (69) 17 alpha-methyl-androstan-3-hydroxyimine-17 beta-ol; |
| 13 | <pre>(70) 17 beta-hydroxy-androstano[2,3-d]isoxazole;</pre> |
| 14 | <pre>(71) 17 beta-hydroxy-androstano[3,2-c]isoxazole;</pre> |
| 15 | (72) 18a-homo-3-hydroxy-estra-2,5(10)-dien-17-one; |
| 16 | (73) 2 alpha, 3 alpha-epithio-17 alpha-methyl-5 alpha-androstan-17 |
| 17 | beta-ol; |
| 18 | (74) 4-chloro-17 alpha-methyl-17 beta-hydroxy-androst-4-en-3-one; |
| 19 | (75) 4-chloro-17 alpha-methyl-17 beta-hydroxy-androst-4-en-3,11- |
| 20 | dione; |
| 21 | (76) 4-chloro-17 alpha-methyl-androst-4-ene-3 beta,17 beta-diol; |
| 22 | (77) 4-chloro-17 alpha-methyl-androsta-1,4,diene-3,17 beta-diol; |
| 23 | <pre>(78) 4-hydroxy-androst-4-ene-3,17-dione;</pre> |
| 24 | (79) 5 alpha-Androstan-3,6,17-trione; |
| 25 | <pre>(80) 6-bromo-androst-1,4-diene-3,17-dione;</pre> |
| 26 | <pre>(81) 6-bromo-androstan-3,17-dione;</pre> |
| 27 | <pre>(82) 6 alpha-methyl-androst-4-ene-3,17-dione;</pre> |
| 28 | (83) Delta 1-dihydrotestosterone; |
| 29 | (84) Estra-4,9,11-triene-3,17-dione; and |
| 30 | (85) Any salt, ester, or ether of a drug or substance described or |
| 31 | listed in this subdivision if the salt, ester, or ether promotes muscle |

1 growth. 2 (e) Hallucinogenic substances known as: 3 (1) Dronabinol, synthetic, in sesame oil and encapsulated in a soft gelatin capsule in a drug product approved by the federal Food and Drug 4 5 Administration. Some other names for dronabinol are (6aRtrans)-6a,7,8,10a-tetrahydro-6,6,9-trimethyl-3-pentyl-6H-dibenzo 6 7 (b,d)pyran-1-ol or (-)-delta-9-(trans)-tetrahydrocannabinol. 8 Schedule IV 9 (a) Any material, compound, mixture, or preparation which contains any quantity of the following substances, including their salts, isomers, 10 and salts of isomers whenever the existence of such salts, isomers, and 11 salts of isomers is possible within the specific chemical designation: 12 13 (1) Barbital; (2) Chloral betaine; 14 (3) Chloral hydrate; 15 16 (4) Chlordiazepoxide, but not including librax (chlordiazepoxide hydrochloride and clindinium bromide) or menrium (chlordiazepoxide and 17 water soluble esterified estrogens); 18 19 (5) Clonazepam; (6) Clorazepate; 20 21 (7) Diazepam; 22 (8) Ethchlorvynol; (9) Ethinamate; 23 24 (10) Flurazepam; 25 (11) Mebutamate; (12) Meprobamate; 26 27 (13) Methohexital; 28 (14) Methylphenobarbital; (15) Oxazepam; 29 30 (16) Paraldehyde; (17) Petrichloral; 31

| 1 | (18) | Phenobarbital; |
|----|------|--------------------|
| 2 | (19) | Prazepam; |
| 3 | (20) | Alprazolam; |
| 4 | (21) | Bromazepam; |
| 5 | (22) | Camazepam; |
| 6 | (23) | Clobazam; |
| 7 | (24) | Clotiazepam; |
| 8 | (25) | Cloxazolam; |
| 9 | (26) | Delorazepam; |
| 10 | (27) | Estazolam; |
| 11 | (28) | Ethyl loflazepate; |
| 12 | (29) | Fludiazepam; |
| 13 | (30) | Flunitrazepam; |
| 14 | (31) | Halazepam; |
| 15 | (32) | Haloxazolam; |
| 16 | (33) | Ketazolam; |
| 17 | (34) | Loprazolam; |
| 18 | (35) | Lorazepam; |
| 19 | (36) | Lormetazepam; |
| 20 | (37) | Medazepam; |
| 21 | (38) | Nimetazepam; |
| 22 | (39) | Nitrazepam; |
| 23 | (40) | Nordiazepam; |
| 24 | (41) | Oxazolam; |
| 25 | (42) | Pinazepam; |
| 26 | (43) | Temazepam; |
| 27 | (44) | Tetrazepam; |
| 28 | (45) | Triazolam; |
| 29 | (46) | Midazolam; |
| 30 | (47) | Quazepam; |
| 31 | (48) | Zolpidem; |

| LB22 2023 | LB22 2023 |
|--------------|---|
| 1 | (49) Dichloralphenazone; |
| 2 | (50) Zaleplon; |
| 3 | (51) Zopiclone; |
| 4 | (52) Fospropofol; |
| 5 | (53) Alfaxalone; |
| 6 | (54) Suvorexant; |
| 7 | (55) Carisoprodol; |
| 8 | (56) Brexanolone; 3 alpha-hydroxy-5 alpha-pregnan-20-one; |
| 9 | (57) Lemborexant; |
| 10 | (58) Solriamfetol; 2-amino-3-phenylpropyl carbamate; |
| 11 | (59) Remimazolam; and |
| 12 | (60) Serdexmethylphenidate. |
| 13 | (b) Any material, compound, mixture, or preparation which contains |
| 14 | any quantity of the following substance, including its salts, isomers, |
| 15 | whether optical, position, or geometric, and salts of such isomers, |
| 16 | whenever the existence of such salts, isomers, and salts of isomers is |
| 17 | possible: Fenfluramine. |
| 18 | (c) Unless specifically excepted or unless listed in another |
| 19 | schedule, any material, compound, mixture, or preparation which contains |
| 20 | any quantity of the following substances having a stimulant effect on the |
| 21 | central nervous system, including their salts, isomers, whether optical, |
| 22 | position, or geometric, and salts of such isomers whenever the existence |

23 of such salts, isomers, and salts of isomers is possible within the 24 specific chemical designation:

25 (1) Diethylpropion;

26 (2) Phentermine;

27 (3) Pemoline, including organometallic complexes and chelates28 thereof;

29 (4) Mazindol;

30 (5) Pipradrol;

31 (6) SPA, ((-)-1-dimethylamino- 1,2-diphenylethane);

-47-

1 (7) Cathine. Another name for cathine is ((+)-norpseudoephedrine);

2 (8) Fencamfamin;

3 (9) Fenproporex;

4 (10) Mefenorex;

5 (11) Modafinil; and

6 (12) Sibutramine.

7 (d) Unless specifically excepted or unless listed in another 8 schedule, any material, compound, mixture, or preparation which contains 9 any quantity of the following narcotic drugs, or their salts or isomers 10 calculated as the free anhydrous base or alkaloid, in limited quantities 11 as set forth below:

12 (1) Propoxyphene in manufactured dosage forms;

13 (2) Not more than one milligram of difenoxin and not less than
14 twenty-five micrograms of atropine sulfate per dosage unit; and

(3) 2-[(dimethylamino)methyl]-1-(3-methoxyphenyl)cyclohexanol, its
salts, optical and geometric isomers, and salts of these isomers to
include: Tramadol.

(e) Unless specifically excepted or unless listed in another
schedule, any material, compound, mixture, or preparation which contains
any quantity of the following substance, including its salts:

21 (1) Pentazocine; and

22 (2) Butorphanol (including its optical isomers).

(f) Any material, compound, mixture, or preparation which contains
any quantity of the following substances, including its salts, isomers,
and salts of such isomers, whenever the existence of such salts, isomers,
and salts of isomers is possible: Lorcaserin.

(g)(1) Unless specifically excepted or unless listed in another
schedule, any material, compound, mixture, or preparation which contains
any quantity of the following substance, including its salts, optical
isomers, and salts of such optical isomers: Ephedrine.

31 (2) The following drug products containing ephedrine, its salts,

-48-

optical isomers, and salts of such optical isomers, are excepted from 1 2 subdivision (g)(1) of Schedule IV if they (A) are stored behind a counter, in an area not accessible to customers, or in a locked case so 3 4 that a customer needs assistance from an employee to access the drug 5 product; (B) are sold by a person, eighteen years of age or older, in the course of his or her employment to a customer eighteen years of age or 6 older with the following restrictions: No customer shall be allowed to 7 purchase, receive, or otherwise acquire more than three and six-tenths 8 9 grams of ephedrine base during a twenty-four-hour period; no customer 10 shall purchase, receive, or otherwise acquire more than nine grams of ephedrine base during a thirty-day period; and the customer shall display 11 a valid driver's or operator's license, a Nebraska state identification 12 card, a military identification card, an alien registration card, or a 13 passport as proof of identification; (C) are labeled and marketed in a 14 manner consistent with the pertinent OTC Tentative Final or Final 15 16 Monograph; (D) are manufactured and distributed for legitimate medicinal use in a manner that reduces or eliminates the likelihood of abuse; and 17 (E) are not marketed, advertised, or represented in any manner for the 18 indication of stimulation, mental alertness, euphoria, ecstasy, a buzz or 19 high, heightened sexual performance, or increased muscle mass: 20

21 (i) Primatene Tablets; and

22 (ii) Bronkaid Dual Action Caplets.

23 Schedule V

(a) Any compound, mixture, or preparation containing any of the
following limited quantities of narcotic drugs or salts calculated as the
free anhydrous base or alkaloid, which shall include one or more
nonnarcotic active medicinal ingredients in sufficient proportion to
confer upon the compound, mixture, or preparation valuable medicinal
qualities other than those possessed by the narcotic drug alone:

30 (1) Not more than two hundred milligrams of codeine per one hundred
 31 milliliters or per one hundred grams;

-49-

(2) Not more than one hundred milligrams of dihydrocodeine per one
 hundred milliliters or per one hundred grams;

3 (3) Not more than one hundred milligrams of ethylmorphine per one
4 hundred milliliters or per one hundred grams;

5 (4) Not more than two and five-tenths milligrams of diphenoxylate 6 and not less than twenty-five micrograms of atropine sulfate per dosage 7 unit;

8 (5) Not more than one hundred milligrams of opium per one hundred 9 milliliters or per one hundred grams; and

10 (6) Not more than five-tenths milligram of difenoxin and not less
11 than twenty-five micrograms of atropine sulfate per dosage unit.

(b) Unless specifically exempted or excluded or unless listed in another schedule, any material, compound, mixture, or preparation which contains any quantity of the following substances having a stimulant effect on the central nervous system, including its salts, isomers, and salts of isomers: Pyrovalerone.

(c) Unless specifically exempted or excluded or unless listed in another schedule, any material, compound, mixture, or preparation which contains any quantity of the following substances having a depressant effect on the central nervous system, including its salts, isomers, and salts of isomers:

(1) Ezogabine (N-(2-amino-4-(4-fluorobenzylamino)-phenyl)-carbamic
 acid ethyl ester);

24 (2) Lacosamide ((R)-2-acetoamido-N-benzyl-3-methoxy-propionamide);

25 (

(3) Pregabalin ((S)-3-(aminomethyl)-5-methylhexanoic acid);

26 (4) Brivaracetam ((2S)-2-[(4R)-2-oxo-4-propylpyrrolidin-1-yl]
27 butanamide) (also referred to as BRV; UCB-34714; Briviact), including its
28 salts;

29 (5) Cenobamate; and

30 (6) Lasmiditan.

31 Sec. 6. Section 28-416, Revised Statutes Cumulative Supplement,

-50-

1 2022, is amended to read:

2 28-416 (1) Except as authorized by the Uniform Controlled Substances 3 Act, it shall be unlawful for any person knowingly or intentionally: (a) 4 To manufacture, distribute, deliver, dispense, or possess with intent to 5 manufacture, distribute, deliver, or dispense a controlled substance; or 6 (b) to create, distribute, or possess with intent to distribute a 7 counterfeit controlled substance.

(2) Except as provided in subsections (4), (5), (7), (8), (9), and 8 9 (10) of this section, any person who violates subsection (1) of this section with respect to: (a) A controlled substance classified in 10 Schedule I, II, or III of section 28-405 which is an exceptionally 11 hazardous drug shall be guilty of a Class II felony; (b) any other 12 controlled substance classified in Schedule I, II, or III of section 13 28-405 shall be quilty of a Class IIA felony; or (c) a controlled 14 substance classified in Schedule IV or V of section 28-405 shall be 15 guilty of a Class IIIA felony. 16

(3) A person knowingly or intentionally possessing a controlled 17 substance, except marijuana or any substance containing a quantifiable 18 amount of the substances, chemicals, or compounds described, defined, or 19 delineated in subdivision (c)(25) (c)(26) of Schedule I of section 20 28-405, unless such substance was obtained directly or pursuant to a 21 medical order issued by a practitioner authorized to prescribe while 22 23 acting in the course of his or her professional practice, or except as 24 otherwise authorized by the act, shall be guilty of a Class IV felony. A 25 person shall not be in violation of this subsection if section 28-472 or 28-1701 applies. 26

(4)(a) Except as authorized by the Uniform Controlled Substances Act, any person eighteen years of age or older who knowingly or intentionally manufactures, distributes, delivers, dispenses, or possesses with intent to manufacture, distribute, deliver, or dispense a controlled substance or a counterfeit controlled substance (i) to a

-51-

person under the age of eighteen years, (ii) in, on, or within one 1 thousand feet of the real property comprising a public or private 2 3 elementary, vocational, or secondary school, a community college, a 4 public or private college, junior college, or university, or a playground, or (iii) within one hundred feet of a public or private youth 5 center, public swimming pool, or video arcade facility shall be punished 6 by the next higher penalty classification than the penalty prescribed in 7 subsection (2), (7), (8), (9), or (10) of this section, depending upon 8 9 the controlled substance involved, for the first violation and for a second or subsequent violation shall be punished by the next higher 10 penalty classification than that prescribed for a first violation of this 11 subsection, but in no event shall such person be punished by a penalty 12 greater than a Class IB felony. 13

14

(b) For purposes of this subsection:

(i) Playground means any outdoor facility, including any parking lot
appurtenant to the facility, intended for recreation, open to the public,
and with any portion containing three or more apparatus intended for the
recreation of children, including sliding boards, swingsets, and
teeterboards;

(ii) Video arcade facility means any facility legally accessible to
persons under eighteen years of age, intended primarily for the use of
pinball and video machines for amusement, and containing a minimum of ten
pinball or video machines; and

(iii) Youth center means any recreational facility or gymnasium,
including any parking lot appurtenant to the facility or gymnasium,
intended primarily for use by persons under eighteen years of age which
regularly provides athletic, civic, or cultural activities.

(5)(a) Except as authorized by the Uniform Controlled Substances
Act, it shall be unlawful for any person eighteen years of age or older
to knowingly and intentionally employ, hire, use, cause, persuade, coax,
induce, entice, seduce, or coerce any person under the age of eighteen

-52-

years to manufacture, transport, distribute, carry, deliver, dispense,
 prepare for delivery, offer for delivery, or possess with intent to do
 the same a controlled substance or a counterfeit controlled substance.

4 (b) Except as authorized by the Uniform Controlled Substances Act, it shall be unlawful for any person eighteen years of age or older to 5 knowingly and intentionally employ, hire, use, cause, persuade, coax, 6 7 induce, entice, seduce, or coerce any person under the age of eighteen years to aid and abet any person in the manufacture, transportation, 8 distribution, carrying, delivery, dispensing, preparation for delivery, 9 offering for delivery, or possession with intent to do the same of a 10 controlled substance or a counterfeit controlled substance. 11

(c) Any person who violates subdivision (a) or (b) of this 12 13 subsection shall be punished by the next higher penalty classification than the penalty prescribed in subsection (2), (7), (8), (9), or (10) of 14 this section, depending upon the controlled substance involved, for the 15 first violation and for a second or subsequent violation shall be 16 punished by the next higher penalty classification than that prescribed 17 for a first violation of this subsection, but in no event shall such 18 person be punished by a penalty greater than a Class IB felony. 19

(6) It shall not be a defense to prosecution for violation of
subsection (4) or (5) of this section that the defendant did not know the
age of the person through whom the defendant violated such subsection.

(7) Any person who violates subsection (1) of this section with
respect to cocaine or any mixture or substance containing a detectable
amount of cocaine in a quantity of:

26 (a) One hundred forty grams or more shall be guilty of a Class IB27 felony;

(b) At least twenty-eight grams but less than one hundred fortygrams shall be guilty of a Class IC felony; or

30 (c) At least ten grams but less than twenty-eight grams shall be31 guilty of a Class ID felony.

-53-

(8) Any person who violates subsection (1) of this section with
 respect to base cocaine (crack) or any mixture or substance containing a
 detectable amount of base cocaine in a quantity of:

4 (a) One hundred forty grams or more shall be guilty of a Class IB5 felony;

6 (b) At least twenty-eight grams but less than one hundred forty7 grams shall be guilty of a Class IC felony; or

8 (c) At least ten grams but less than twenty-eight grams shall be9 guilty of a Class ID felony.

(9) Any person who violates subsection (1) of this section with
respect to heroin or any mixture or substance containing a detectable
amount of heroin in a quantity of:

13 (a) One hundred forty grams or more shall be guilty of a Class IB14 felony;

(b) At least twenty-eight grams but less than one hundred fortygrams shall be guilty of a Class IC felony; or

17 (c) At least ten grams but less than twenty-eight grams shall be18 guilty of a Class ID felony.

(10) Any person who violates subsection (1) of this section with respect to amphetamine, its salts, optical isomers, and salts of its isomers, or with respect to methamphetamine, its salts, optical isomers, and salts of its isomers, in a quantity of:

(a) One hundred forty grams or more shall be guilty of a Class IBfelony;

(b) At least twenty-eight grams but less than one hundred forty
grams shall be guilty of a Class IC felony; or

(c) At least ten grams but less than twenty-eight grams shall beguilty of a Class ID felony.

(11) Any person knowingly or intentionally possessing marijuana
 weighing more than one ounce but not more than one pound shall be guilty
 of a Class III misdemeanor.

-54-

(12) Any person knowingly or intentionally possessing marijuana weighing more than one pound shall be guilty of a Class IV felony.

3 (11) (13) Except as provided in section 28-1701, any person
4 knowingly or intentionally possessing marijuana weighing one ounce or
5 less or any substance containing a quantifiable amount of the substances,
6 chemicals, or compounds described, defined, or delineated in subdivision
7 (c)(25) (c)(26) of Schedule I of section 28-405 shall:

8 (a) For the first offense, be guilty of an infraction, receive a 9 citation, be fined three hundred dollars, and be assigned to attend a 10 course as prescribed in section 29-433 if the judge determines that 11 attending such course is in the best interest of the individual 12 defendant;

(b) For the second offense, be guilty of a Class IV misdemeanor,
receive a citation, and be fined four hundred dollars and may be
imprisoned not to exceed five days; and

(c) For the third and all subsequent offenses, be guilty of a Class
IIIA misdemeanor, receive a citation, be fined five hundred dollars, and
be imprisoned not to exceed seven days.

19 (12) (14) Any person convicted of violating this section, if placed 20 on probation, shall, as a condition of probation, satisfactorily attend 21 and complete appropriate treatment and counseling on drug abuse provided 22 by a program authorized under the Nebraska Behavioral Health Services Act 23 or other licensed drug treatment facility.

(13) (15) Any person convicted of violating this section, if
 sentenced to the Department of Correctional Services, shall attend
 appropriate treatment and counseling on drug abuse.

27 (14) (16) Any person knowingly or intentionally possessing a firearm 28 while in violation of subsection (1) of this section shall be punished by 29 the next higher penalty classification than the penalty prescribed in 30 subsection (2), (7), (8), (9), or (10) of this section, but in no event 31 shall such person be punished by a penalty greater than a Class IB

-55-

1 felony.

2 (15) (17) A person knowingly or intentionally in possession of money
3 used or intended to be used to facilitate a violation of subsection (1)
4 of this section shall be guilty of a Class IV felony.

(16) (18) In addition to the existing penalties available for a 5 violation of subsection (1) of this section, including any criminal 6 attempt or conspiracy to violate subsection (1) of this section, a 7 sentencing court may order that any money, securities, negotiable 8 9 instruments, firearms, conveyances, or electronic communication devices as defined in section 28-833 or any equipment, components, peripherals, 10 software, hardware, or accessories related to electronic communication 11 devices be forfeited as a part of the sentence imposed if it finds by 12 13 clear and convincing evidence adduced at a separate hearing in the same prosecution, following conviction for a violation of subsection (1) of 14 this section, and conducted pursuant to section 28-1601, that any or all 15 such property was derived from, used, or intended to be used to 16 facilitate a violation of subsection (1) of this section. 17

18

(17) (19) In addition to the penalties provided in this section:

(a) If the person convicted or adjudicated of violating this section
is eighteen years of age or younger and has one or more licenses or
permits issued under the Motor Vehicle Operator's License Act:

(i) For the first offense, the court may, as a part of the judgment
of conviction or adjudication, (A) impound any such licenses or permits
for thirty days and (B) require such person to attend a drug education
class;

(ii) For a second offense, the court may, as a part of the judgment of conviction or adjudication, (A) impound any such licenses or permits for ninety days and (B) require such person to complete no fewer than twenty and no more than forty hours of community service and to attend a drug education class; and

31

(iii) For a third or subsequent offense, the court may, as a part of

-56-

the judgment of conviction or adjudication, (A) impound any such licenses or permits for twelve months and (B) require such person to complete no fewer than sixty hours of community service, to attend a drug education class, and to submit to a drug assessment by a licensed alcohol and drug counselor; and

6 (b) If the person convicted or adjudicated of violating this section 7 is eighteen years of age or younger and does not have a permit or license 8 issued under the Motor Vehicle Operator's License Act:

9 (i) For the first offense, the court may, as part of the judgment of 10 conviction or adjudication, (A) prohibit such person from obtaining any 11 permit or any license pursuant to the act for which such person would 12 otherwise be eligible until thirty days after the date of such order and 13 (B) require such person to attend a drug education class;

(ii) For a second offense, the court may, as part of the judgment of conviction or adjudication, (A) prohibit such person from obtaining any permit or any license pursuant to the act for which such person would otherwise be eligible until ninety days after the date of such order and (B) require such person to complete no fewer than twenty hours and no more than forty hours of community service and to attend a drug education class; and

(iii) For a third or subsequent offense, the court may, as part of the judgment of conviction or adjudication, (A) prohibit such person from obtaining any permit or any license pursuant to the act for which such person would otherwise be eligible until twelve months after the date of such order and (B) require such person to complete no fewer than sixty hours of community service, to attend a drug education class, and to submit to a drug assessment by a licensed alcohol and drug counselor.

A copy of an abstract of the court's conviction or adjudication shall be transmitted to the Director of Motor Vehicles pursuant to sections 60-497.01 to 60-497.04 if a license or permit is impounded or a juvenile is prohibited from obtaining a license or permit under this

-57-

6

1 subsection.

2 (18) It shall not be an offense for a person to use or possess
3 marijuana.

4 Sec. 7. Section 28-417, Reissue Revised Statutes of Nebraska, is 5 amended to read:

28-417 (1) It shall be unlawful for any person:

7 (a) To omit, remove, alter, or obliterate a symbol required by the
8 federal Controlled Substances Act, 21 U.S.C. 801 et seq., as the act
9 existed on September 1, 2001, or required by the laws of this state;

10 (b) To alter, deface, or remove any label affixed to a package of11 narcotic drugs;

12 (c) To refuse or fail to make, keep, or furnish any record,
13 notification, order form, statement, invoice, or information required
14 under the Uniform Controlled Substances Act;

(d) To refuse any entry into any premises for inspection authorizedby the act;

(e) To keep or maintain any store, shop, warehouse, dwelling house, building, vehicle, boat, aircraft, or place whatever which such person knows or should know is resorted to by persons using controlled substances in violation of the Uniform Controlled Substances Act for the purpose of using such substances or which is used for the keeping or selling of the same in violation of the act;

(f) To whom or for whose use any controlled substance has been prescribed, sold, or dispensed by a practitioner or the owner of any animal for which any such substance has been prescribed, sold, or dispensed by a veterinarian to possess it in a container other than which it was delivered to him or her by the practitioner; or

(g) To be under the influence of any controlled substance, other
<u>than marijuana</u>, for a purpose other than the treatment of a sickness or
injury as prescribed or administered by a practitioner. In a prosecution
under this subdivision, it shall not be necessary for the state to prove

-58-

1 that the accused was under the influence of any specific controlled 2 substance, but it shall be sufficient for a conviction under this 3 subdivision for the state to prove that the accused was under the 4 influence of some controlled substance by proving that the accused did 5 manifest physical and physiological symptoms or reactions caused by the 6 use of any controlled substance.

7 (2) Any person who violates this section shall be guilty of a Class8 III misdemeanor.

9 Sec. 8. Section 28-419, Reissue Revised Statutes of Nebraska, is 10 amended to read:

28-419 (1) No person shall breathe, inhale, or drink any compound, 11 liquid, or chemical containing acetate, acetone, benzene, butyl alcohol, 12 13 cyclohexanone, ethyl acetate, ethyl alcohol, ethylene dichloride, ethylene trichloride, hexane, isopropanol, isopropyl alcohol, methyl 14 alcohol, methyl cellosolve acetate, methyl ethyl ketone, methyl isobutyl 15 ketone, pentachlorophenol, petroleum ether, toluene, 16 toluol, 17 trichloroathane, trichloroethylene, or any other substance for the inducing a condition of intoxication, 18 purpose of stupefaction, depression, giddiness, paralysis, inebriation, excitement, or irrational 19 behavior, or in any manner changing, distorting, or disturbing the 20 auditory, visual, mental, or nervous processes. For the purposes of 21 22 sections 28-419 to 28-424, any such condition so induced shall be deemed 23 an intoxicated condition.

24

(2) This section does not apply to the use of marijuana.

25 Sec. 9. Section 28-439, Reissue Revised Statutes of Nebraska, is 26 amended to read:

27 28-439 <u>(1)</u> As used in sections 28-101, 28-431, and 28-439 to 28 28-444, unless the context otherwise requires, drug paraphernalia shall 29 mean all equipment, products, and materials of any kind which are used, 30 intended for use, or designed for use, in manufacturing, injecting, 31 ingesting, inhaling, or otherwise introducing into the human body a

-59-

1 controlled substance in violation of sections 28-101, 28-431, and 28-439
2 to 28-444 or the Uniform Controlled Substances Act. It shall include, but
3 not be limited to, the following:

4 (a) (1) Diluents and adulterants, such as quinine hydrochloride,
5 mannitol, mannite, dextrose, and lactose, used, intended for use, or
6 designed for use in cutting controlled substances;

7 (2) Separation gins and sifters used, intended for use, or designed
8 for use in removing twigs and seeds from, or in otherwise cleaning or
9 refining, marijuana;

10 <u>(b)</u> (3) Hypodermic syringes, needles, and other objects used, 11 intended for use, and designed for use in parenterally injecting 12 controlled substances into the human body; and

(c) (4) Objects used, intended for use, or designed for use in
 ingesting, inhaling, or otherwise introducing marijuana, cocaine,
 hashish, or hashish oil into the human body., which shall include but
 not be limited to the following:

17 (2) Items used or intended for use in the consumption, manufacture,
 18 cultivation, or processing of marijuana shall not be considered drug
 19 paraphernalia.

20 (a) Metal, wooden, acrylic, glass, stone, plastic, or ceramic pipes
 21 with or without screens, permanent screens, hashish heads, or punctured
 22 metal bowls;

23 (b) Water pipes;

24 (c) Carburetion tubes and devices;

25 (d) Smoking and carburetion masks;

26 (e) Roach clips, meaning objects used to hold burning material, such 27 as a marijuana cigarette, which has become too small or too short to be 28 held in the hand;

29 (f) Miniature cocaine spoons, and cocaine vials;

30 (g) Chamber pipes;

31 (h) Carburetor pipes;

1 (i) Electric pipes;

2 (j) Air-driven pipes;

3 (k) Chillums;

4 (1) Bongs; and

5 (m) Ice pipes or chillers.

Sec. 10. Section 28-1354, Revised Statutes Cumulative Supplement,
2022, is amended to read:

8

28-1354 For purposes of the Public Protection Act:

9 (1)Enterprise means any individual, sole proprietorship, partnership, corporation, trust, association, or any legal entity, union, 10 or group of individuals associated in fact although not a legal entity, 11 and shall include illicit as well as licit enterprises as well as other 12 13 entities;

(2) Pattern of racketeering activity means a cumulative loss for one or more victims or gains for the enterprise of not less than one thousand five hundred dollars resulting from at least two acts of racketeering activity, one of which occurred after August 30, 2009, and the last of which occurred within ten years, excluding any period of imprisonment, after the commission of a prior act of racketeering activity;

(3) Until January 1, 2017, person means any individual or entity, as
defined in section 21-2014, holding or capable of holding a legal,
equitable, or beneficial interest in property. Beginning January 1, 2017,
person means any individual or entity, as defined in section 21-214,
holding or capable of holding a legal, equitable, or beneficial interest
in property;

(4) Prosecutor includes the Attorney General of the State of
Nebraska, the deputy attorney general, assistant attorneys general, a
county attorney, a deputy county attorney, or any person so designated by
the Attorney General, a county attorney, or a court of the state to carry
out the powers conferred by the act;

31 (5) Racketeering activity includes the commission of, criminal

-61-

1 attempt to commit, conspiracy to commit, aiding and abetting in the 2 commission of, aiding in the consummation of, acting as an accessory to 3 the commission of, or the solicitation, coercion, or intimidation of 4 another to commit or aid in the commission of any of the following:

5 (a) Offenses against the person which include: Murder in the first degree under section 28-303; murder in the second degree under section 6 7 28-304; manslaughter under section 28-305; assault in the first degree under section 28-308; assault in the second degree under section 28-309; 8 9 assault in the third degree under section 28-310; terroristic threats 10 under section 28-311.01; kidnapping under section 28-313; false imprisonment in the first degree under section 28-314; false imprisonment 11 in the second degree under section 28-315; sexual assault in the first 12 degree under section 28-319; and robbery under section 28-324; 13

(b) Offenses relating to controlled substances which include: To 14 unlawfully manufacture, distribute, deliver, dispense, or possess with 15 intent to manufacture, distribute, deliver, or dispense a controlled 16 17 substance under subsection (1) of section 28-416; possession of marijuana weighing more than one pound under subsection (12) of section 28-416; 18 19 possession of money used or intended to be used to facilitate a violation of subsection (1) of section 28-416 prohibited under subsection (15) (17)20 of section 28-416; any violation of section 28-418; to unlawfully 21 22 manufacture, distribute, deliver, or possess with intent to distribute or 23 an imitation controlled substance under section deliver 28-445; 24 possession of anhydrous ammonia with the intent to manufacture 25 methamphetamine under section 28-451; and possession of ephedrine, pseudoephedrine, or phenylpropanolamine with the intent to manufacture 26 methamphetamine under section 28-452; 27

(c) Offenses against property which include: Arson in the first
degree under section 28-502; arson in the second degree under section
28-503; arson in the third degree under section 28-504; burglary under
section 28-507; theft by unlawful taking or disposition under section

-62-

1 28-511; theft by shoplifting under section 28-511.01; theft by deception 2 under section 28-512; theft by extortion under section 28-513; theft of 3 services under section 28-515; theft by receiving stolen property under 4 section 28-517; criminal mischief under section 28-519; and unlawfully 5 depriving or obtaining property or services using a computer under 6 section 28-1344;

(d) Offenses involving fraud which include: Burning to defraud an 7 insurer under section 28-505; forgery in the first degree under section 8 9 28-602; forgery in the second degree under section 28-603; criminal possession of a forged instrument under section 28-604; criminal 10 possession of written instrument forgery devices under section 28-605; 11 criminal impersonation under section 28-638; identity theft under section 12 13 28-639; identity fraud under section 28-640; false statement or book entry under section 28-612; tampering with a publicly exhibited contest 14 under section 28-614; issuing a false financial statement for purposes of 15 16 obtaining a financial transaction device under section 28-619; 17 unauthorized use of a financial transaction device under section 28-620; criminal possession of a financial transaction device under section 18 28-621; unlawful circulation of a financial transaction device in the 19 first degree under section 28-622; unlawful circulation of a financial 20 transaction device in the second degree under section 28-623; criminal 21 possession of a blank financial transaction device under section 28-624; 22 criminal sale of a blank financial transaction device under section 23 24 28-625; criminal possession of a financial transaction forgery device 25 under section 28-626; unlawful manufacture of a financial transaction device under section 28-627; laundering of sales forms under section 26 28-628; unlawful acquisition of sales form processing services under 27 28 section 28-629; unlawful factoring of a financial transaction device under section 28-630; and fraudulent insurance acts under section 28-631; 29 (e) Offenses involving governmental operations which include: Abuse 30 of public records under section 28-911; perjury or subornation of perjury 31

-63-

under section 28-915; bribery under section 28-917; bribery of a witness 1 2 under section 28-918; tampering with a witness or informant or jury tampering under section 28-919; bribery of a juror under section 28-920; 3 4 assault on an officer, an emergency responder, a state correctional 5 employee, a Department of Health and Human Services employee, or a health care professional in the first degree under section 28-929; assault on an 6 officer, an emergency responder, a state correctional employee, a 7 Department of Health and Human Services employee, or a health care 8 9 professional in the second degree under section 28-930; assault on an officer, an emergency responder, a state correctional employee, a 10 Department of Health and Human Services employee, or a health care 11 professional in the third degree under section 28-931; and assault on an 12 officer, an emergency responder, a state correctional employee, a 13 14 Department of Health and Human Services employee, or a health care professional using a motor vehicle under section 28-931.01; 15

(f) Offenses involving gambling which include: Promoting gambling in
the first degree under section 28-1102; possession of gambling records
under section 28-1105; gambling debt collection under section 28-1105.01;
and possession of a gambling device under section 28-1107;

(g) Offenses relating to firearms, weapons, and explosives which 20 21 include: Carrying а concealed weapon under section 28-1202; 22 transportation or possession of machine guns, short rifles, or short 23 shotguns under section 28-1203; unlawful possession of a handgun under 24 section 28-1204; unlawful transfer of a firearm to a juvenile under 25 section 28-1204.01; possession of a firearm by a prohibited juvenile offender under section 28-1204.05; using a deadly weapon to commit a 26 felony or possession of a deadly weapon during the commission of a felony 27 under section 28-1205; possession of a deadly weapon by a prohibited 28 person under section 28-1206; possession of a defaced firearm under 29 section 28-1207; defacing a firearm under section 28-1208; unlawful 30 discharge of a firearm under section 28-1212.02; possession, receipt, 31

-64-

retention, or disposition of a stolen firearm under section 28-1212.03; 1 2 unlawful possession of explosive materials in the first degree under section 28-1215; unlawful possession of explosive materials in the second 3 4 degree under section 28-1216; unlawful sale of explosives under section 5 28-1217; use of explosives without a permit under section 28-1218; obtaining an explosives permit through false representations under 6 section 28-1219; possession of a destructive device under section 7 28-1220; threatening the use of explosives or placing a false bomb under 8 9 section 28-1221; using explosives to commit a felony under section 10 28-1222; using explosives to damage or destroy property under section 28-1223; and using explosives to kill or injure any person under section 11 28-1224; 12

13 (h) Any violation of the Securities Act of Nebraska pursuant to14 section 8-1117;

(i) Any violation of the Nebraska Revenue Act of 1967 pursuant tosection 77-2713;

(j) Offenses relating to public health and morals which include: Prostitution under section 28-801; pandering under section 28-802; keeping a place of prostitution under section 28-804; labor trafficking, sex trafficking, labor trafficking of a minor, or sex trafficking of a minor under section 28-831; a violation of section 28-1005; and any act relating to the visual depiction of sexually explicit conduct prohibited in the Child Pornography Prevention Act; and

24

(k) A violation of the Computer Crimes Act;

(6) State means the State of Nebraska or any political subdivision
or any department, agency, or instrumentality thereof; and

(7) Unlawful debt means a debt of at least one thousand five hundreddollars:

(a) Incurred or contracted in gambling activity which was in
violation of federal law or the law of the state or which is
unenforceable under state or federal law in whole or in part as to

-65-

1 principal or interest because of the laws relating to usury; or

2 (b) Which was incurred in connection with the business of gambling 3 in violation of federal law or the law of the state or the business of 4 lending money or a thing of value at a rate usurious under state law if 5 the usurious rate is at least twice the enforceable rate.

Sec. 11. Section 28-1701, Revised Statutes Cumulative Supplement,
2022, is amended to read:

8 28-1701 (1) A person shall not be arrested or prosecuted for an 9 eligible alcohol or drug offense if such person witnessed or was the 10 victim of a sexual assault and such person:

11 (a) Either:

12 (i) In good faith, reported such sexual assault to law enforcement;13 or

14 (ii) Requested emergency medical assistance for the victim of the15 sexual assault; and

(b) Evidence supporting the arrest or prosecution of the eligible
alcohol or drug offense was obtained or discovered as a result of such
person reporting such sexual assault to law enforcement or requesting
emergency medical assistance.

20 (2) A person shall not be arrested or prosecuted for an eligible21 alcohol or drug offense if:

(a) Evidence supporting the arrest or prosecution of the person for
the offense was obtained or discovered as a result of the investigation
or prosecution of a sexual assault; and

(b) Such person cooperates with law enforcement in the investigationor prosecution of the sexual assault.

27 (3) For purposes of this section:

28 (a) Eligible alcohol or drug offense means:

29 (i) A violation of subsection (3) or (11) (13) of section 28-416 or
 30 of section 28-441;

31 (ii) A violation of section 53-180.02 committed by a person older

-66-

1 than eighteen years of age and under the age of twenty-one years, as 2 described in subdivision (4)(a) of section 53-180.05;

3 (iii) A violation of a city or village ordinance similar to
4 subdivision (3)(a)(i) or (ii) of this section; or

5 (iv) Attempt, conspiracy, solicitation, being an accessory to, 6 aiding and abetting, aiding the consummation of, or compounding a felony 7 with any of the offenses in subdivision (3)(a)(i), (ii), or (iii) of this 8 section as the underlying offense; and

9 (b) Sexual assault means:

(i) A violation of section 28-316.01, 28-319, 28-319.01, 28-320,
28-320.01, 28-320.02, 28-322.01, 28-322.02, 28-322.03, 28-322.04,
28-322.05, 28-703, or 28-1463.03, sex trafficking or sex trafficking of a
minor under section 28-831, or subdivision (1)(c) or (g) of section
28-386 or subdivision (1)(d), (e), or (f) of section 28-707; or

(ii) Attempt, conspiracy, solicitation, being an accessory to,
aiding and abetting, aiding the consummation of, or compounding a felony
with any of the offenses listed in subdivision (3)(b)(i) of this section
as the underlying offense.

Sec. 12. Section 77-4301, Reissue Revised Statutes of Nebraska, isamended to read:

21 77-4301 For purposes of sections 77-4301 to 77-4316:

(1) Controlled substance <u>means</u> shall mean any drug or substance,
including an imitation controlled substance, that is held, possessed,
transported, transferred, sold, or offered to be sold in violation of
Nebraska law. Controlled substance <u>does</u> shall not include marijuana;

26 (2) Dealer <u>means</u> shall mean a person who, in violation of Nebraska 27 law, manufactures, produces, ships, transports, or imports into Nebraska 28 or in any manner acquires or possesses six or more ounces of marijuana, 29 seven or more grams of any controlled substance which is sold by weight, 30 or ten or more dosage units of any controlled substance which is not sold 31 by weight;

-67-

(3) Imitation controlled substance <u>has</u> shall have the meaning as
 provided in section 28-401; and

3 (4) Marijuana <u>has</u> shall have the meaning as provided in section
4 28-401.

5 Sec. 13. Section 77-4302, Reissue Revised Statutes of Nebraska, is6 amended to read:

7 77-4302 No dealer may possess marijuana or controlled substances 8 upon which a tax is imposed by section 77-4303 unless the tax has been 9 paid on the marijuana or controlled substance as evidenced by an official 10 stamp, label, or other indicium.

11 Sec. 14. Section 77-4303, Reissue Revised Statutes of Nebraska, is 12 amended to read:

13 77-4303 (1) A tax is hereby imposed on marijuana and controlled 14 substances at the following rates:

15 (a) On each ounce of marijuana or each portion of an ounce, one 16 hundred dollars;

(a) (b) On each gram or portion of a gram of a controlled substance
 that is customarily sold by weight or volume, one hundred fifty dollars;
 or

20 <u>(b)</u> (c) On each fifty dosage units or portion thereof of a 21 controlled substance that is not customarily sold by weight, five hundred 22 dollars.

23 (2) For purposes of calculating the tax under this section, 24 marijuana or any controlled substance that is customarily sold by weight 25 or volume shall be measured by the weight of the substance in the dealer's possession. The weight shall be the actual weight, if known, or 26 the estimated weight as determined by the Nebraska State Patrol or other 27 28 law enforcement agency. Such determination shall be presumed to be the weight of such marijuana or controlled substances for purposes of 29 sections 77-4301 to 77-4316. 30

31 (3) The tax shall not be imposed upon a person registered or

-68-

otherwise lawfully in possession of marijuana or a controlled substance
 pursuant to Chapter 28, article 4.

Sec. 15. Section 77-4304, Reissue Revised Statutes of Nebraska, is
amended to read:

5 77-4304 (1) Subject to the rules and regulations of the Tax 6 Commissioner, official stamps, labels, or other indicia to be affixed to 7 all marijuana and controlled substances shall be purchased from the 8 Department of Revenue. The purchaser shall pay one hundred percent of 9 face value for each official stamp, label, or other indicium purchased 10 and shall not be required to give his or her name, address, social 11 security number, or other identifying information.

12 (2) The Tax Commissioner shall adopt a uniform system of providing, 13 affixing, and displaying an official stamp, label, or other indicium for 14 marijuana and controlled substances on which a tax is imposed. Official 15 stamps, labels, or other indicia shall expire six months from the date of 16 issuance.

Sec. 16. Section 77-4305, Reissue Revised Statutes of Nebraska, is amended to read:

19 77-4305 The tax imposed upon marijuana and controlled substances by 20 section 77-4303 shall be due and payable immediately upon acquisition or 21 possession of marijuana and controlled substances in this state by a 22 dealer.

23 Sec. 17. Section 77-4306, Reissue Revised Statutes of Nebraska, is 24 amended to read:

25 77-4306 If a dealer acquires or ships, transports, or imports into 26 this state marijuana or a controlled substance and if the official stamp, 27 label, or indicium evidencing the payment of the tax has not already been 28 affixed, the dealer shall have it permanently affixed on the marijuana or 29 controlled substance immediately upon acquisition or possession of the 30 marijuana or controlled substance. Each official stamp, label, or other 31 indicium may be used only once.

-69-

Sec. 18. Section 77-4309, Reissue Revised Statutes of Nebraska, is
 amended to read:

3 77-4309 Any dealer violating sections 77-4301 to 77-4316 shall be 4 subject to a penalty of one hundred percent of the tax in addition to the 5 tax imposed by section 77-4303. The penalty shall be collected as part of 6 the tax.

7 A dealer distributing or possessing marijuana or a controlled 8 substance without affixing the official stamp, label, or other indicium 9 shall be guilty of a Class IV felony. Notwithstanding any other provision 10 of the criminal laws of this state, an indictment may be found and filed 11 or an information or complaint filed upon any criminal offense specified 12 in this section in the proper court within six years after the commission 13 of such offense.

Sec. 19. Section 77-4310.01, Reissue Revised Statutes of Nebraska, is amended to read:

16 77-4310.01 Proceeds of the tax imposed by section 77-4303 shall be 17 remitted to the State Treasurer for credit as follows:

(1) Five percent of such proceeds shall be credited to the Marijuana
 and Controlled Substances Tax Administration Cash Fund; and

20

(2) Of the remaining proceeds:

(a) Fifty percent shall be remitted to the respective counties from 21 which the proceeds originated for credit to the County Drug Law 22 Enforcement and Education Fund of each such county. Money remitted to a 23 24 county pursuant to this subdivision shall be remitted to the county 25 treasurer of such county for credit to such fund. For purposes of this subdivision, county from which the proceeds originated shall mean: (i) If 26 the proceeds result from seizure under the Uniform State Tax Lien 27 Registration and Enforcement Act of property located in a county other 28 than the county in which the dealer resides, the county in which the 29 seizure was made; and (ii) in all other cases, the county in which the 30 dealer resides; and 31

-70-

(b) All remaining funds, including those which did not originate in
 a county, shall be credited to the Nebraska State Patrol Drug Control and
 Education Cash Fund.

Sec. 20. Section 77-4310.03, Reissue Revised Statutes of Nebraska,
is amended to read:

77-4310.03 There is hereby created the Marijuana and Controlled 6 Substances Tax Administration Cash Fund. Money in the fund shall be used 7 by the Tax Commissioner for the purposes of administering, collecting, 8 9 and enforcing the tax imposed by section 77-4303, except that transfers 10 may be made from the fund to the General Fund at the direction of the Legislature. Any money in the Marijuana and Controlled Substances Tax 11 Administration Cash Fund available for investment shall be invested by 12 13 the state investment officer pursuant to the Nebraska Capital Expansion Act and the Nebraska State Funds Investment Act. 14

Sec. 21. Original sections 2-505, 2-506, 2-509, 28-417, 28-419,
28-439, 77-4301, 77-4302, 77-4303, 77-4304, 77-4305, 77-4306, 77-4309,
77-4310.01, and 77-4310.03, Reissue Revised Statutes of Nebraska, and
sections 28-401, 28-405, 28-416, 28-1354, and 28-1701, Revised Statutes
Cumulative Supplement, 2022, are repealed.

Sec. 22. The following sections are outright repealed: Sections
2-5701, 28-463, 28-464, 28-465, 28-466, 28-467, 28-468, and 28-469,
Reissue Revised Statutes of Nebraska.

-71-